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ZBTB33 is the first identified zinc finger containing methyl-CpG binding protein 
(MBP), the cellular function of which is still unclear in both normal and disease state. 
Gene regulation by ZBTB33 is mediated through recognition of both methylated as well 
as sequence specific nonmethylated deoxyribonucleic acid (DNA) sites. DNA recognition 
is followed by recruitment of corepressors resulting in transcription changes. While 
evidence suggests that transcriptional regulation by ZBTB33 plays a role in cancer, an 
extensive analysis of the gene targets and signaling pathways regulated by this protein 
have yet to be investigated. The goal of this research is to begin to determine how 
ZBTB33 directs disease relevant transcription. To investigate this, a combination of 
techniques to characterize in cell global gene occupation, DNA methylation status, and 
transcriptome changes were utilized. Further, the effect of bimodal DNA recognition 
exhibited by ZBTB33 on transcriptional regulation and biological pathways in cancer 
were investigated. 
Powerful techniques have emerged for investigating genome-wide protein-DNA 
interactions. One such technique incorporates chromatin immunoprecipitation followed 
by exonuclease digestion and next generation sequencing (ChIP-exo).  While this 
technique maps global gene occupations of transcription factors at high resolution, it also 
harbors technique specific issues, including the significant generation of artifact peaks, 
limiting its application. Thus, a method for generating a background control that 
 	
substantially reduces these artifacts and improves the confidence level in peak 
identification for ChIP-exo data sets was developed. Application of our improved ChIP-
exo method to ZBTB33 revealed additional issues with ChIP-based techniques coupled 
with next generation sequencing that can affect a number of systems.  Thus, efforts to 
identify and resolve these issues are discussed.  
Along with ChIP-based methods, whole genome shotgun bisulfite sequencing 
(WGSBS) and RNA sequencing (RNA-seq) are other powerful methodologies informing 
on the global DNA methylation status and transcriptome of a cell, respectively. By 
combining these techniques with ZBTB33 depletion/overexpression studies and 
phenotypic assays, we found mechanistic details for how ZBTB33 mediates cell-specific 
cell cycle regulation in a cancerous cell line. Specifically, we identified a mechanism by 
which ZBTB33 mediates the cyclin D1/cyclin E1/RB1/E2F pathway, controlling passage 
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Deoxyribonucleic Acid (DNA) methylation in normal cell function 
and disease 
It has been known since 1940 that DNA CpG sites in vertebrates can be 
methylated at the cytosine base, yet it took over 40 years1 to realize the critical role of 
this epigenetic mark in gene regulation.2 Today, it is well established that DNA 
methylation in the context of CpG dinucleotides is present in all mammals and is 
fundamental for controlling gene expression, cell development, cell identity, and 
differentiation. Tight regulation of DNA methylation patterns and propagation to newly 
formed cells must be achieved, as any alterations are often deleterious leading to the 
onset of various diseases.3  In cells, cytosine methylation occurs through the transfer of a 
methyl group from S-adenosyl methionine (SAM) to the five position of the cytosine base 
by DNA methyltransferases (DNMTs) (Figure 1.1).4 DNMT1 functions by ensuring that 
methylation patterns are propagated to nascent oligonucleotides formed during DNA 
replication,4 while DNMT3a and DNMT3b, known as the de novo DNMTs, are 
responsible for establishing new methylation patterns on unmodified DNA during 



























Figure 1.1. Representation of enzymatic DNA methylation by a DNMT. DNMT 
catalyzes the methylation of a cytosine base that precedes a guanosine at carbon 5 by 




In mammals, many methylated DNA sites are found in GC-rich genomic regions 
localized within promoters and gene bodies, referred to as CpG islands (CGIs). In 
addition, high levels of DNA methylation are found at highly repetitive sequences such as 
centromeric regions. In humans, more than 50% of all CpGs are coincident with 
heterochromatin structure while euchromatin regions contain mainly unmethylated 
CGIs.6 Specific global genomic methylation patterns give rise to differential cellular 
phenotypes and are essential for regulating gene expression and maintaining genome 
stability. Open chromatin at unmethylated promoter regions can be targeted by 
transcription factors leading to gene activation, while compacted methylated promoters 
reduce transcriptional accessibility leading to gene silencing.6,7 
Three proposed models explain the inhibitory effect of promoter DNA 
methylation on gene expression (Figure 1.2). The first involves the inability of 
transcription factors to bind their cognate sites due to the presence of CpG methylation. 
In the second model, specialized proteins with high-affinity for recognizing methyl-CpG 
sites, termed methyl-CpG binding proteins (MBPs), hinder promoter binding of 
transcriptional activators. Finally, methylated promoter binding by MBPs recruits 
repressive chromatin modifiers such as histone deacetylases (HDACs) and histone 
methyltransfereases (HMTs) to the target site leading to heterochromatin formation and 
gene repression.8 Interestingly, recent evidence suggests that DNA methylation within 
gene bodies is associated with a higher transcription level in normally proliferating cells 
even when occupied by MBPs.9-12 However, in slowly proliferating cells such as brain 
cells, gene body methylation is associated with a decrease in gene expression.13,14  









Figure 1.2. Mechanisms for gene repression induced via DNA methylation at gene 
promoters. (A) DNA methylation at gene promoters prohibits transcription factor (TF) 
recruitment, leading to gene inactivation. (B) Methyl-CpG binding proteins (MBPs) bind 
to methylated DNA at methylated gene promoters and prevent TF recruitment, resulting 
in gene inactivation. (C) MBPs bind to methylated DNA at methylated gene promoters, 






















nonCpG sites in gene bodies is negatively correlated with gene expression.14 Thus, it is 
increasingly evident that the mechanisms by which DNA methylation regulates gene 
expression are complex. 
 
Histone modifications 
Acetylation and methylation of lysines within histone polypeptide tails are 
prevalent posttranslational epigenetic associated modifications.15 These modifications are 
critical for controlling chromatin structure, which can in turn affect various cellular 
processes such as DNA repair, replication, transcription, and recombination. In contrast 
to DNA methylation, histone modifications are more dynamic.16,17   
Histone acetyltransferases (HATs) acetylate histones by transferring an acetyl 
group from acetyl coenzyme A to specific lysine residues.15 The reverse process is 
mediated by histone deacetylaces (HDACs), which enzymatically remove the acetyl 
groups of histone lysine residues18 (Figure 1.3). Lysine acetylation results in increased 
local negative charges, reducing the affinity between histones and DNA and inducing the 
open chromatin state. Thus, histone acetylation, particularly at H3K9ac, H4K5ac, 
H4K8ac and H2AK5ac, is considered a reliable epigenetic indicator for regions of 
transcriptional activation19 (Figure 1.3). Global changes to histone acetylation patterns in 
humans has been associated with tumorigenesis and cancer progression.20 
Histone methyltransferases (HMTs) catalyze the transfer of a methyl group from 
SAM onto lysines within the polypeptide tails of histones H3 and H4 and in contrast to 
histone acetylation, which primarily leads to gene activation, histone methylation can 





































Figure 1.3. Histone tail posttranslational modifications. Illustration of histone tail 
methylation and acetylation patterns on chromatin structure. Histones can be reversibly 
acetylated and methylated at particular residues. Specific methylation and acetylation 
patterns induce the formation of either heterochromatin or euchromatin structures 





















lysine residue determines the downstream transcriptional outcome. Generally, enriched 
histone methylation at lysine residues can acquire between 1-3 methyl groups, H3K4me2, 
H3K4me3, H3K36me1, or H3K79me1, are indicative of gene activation, while enriched 
histone methylation at H3K9me2, H3K9me3, H4K20me3, or H3K27me3 correlates with 
gene silencing.23   
 
Methyl-CpG binding proteins (MBPs) – interpreters of DNA methylation 
Reading and interpreting the DNA methylation status of genes has been the focus 
of many important studies. Three main families of transcription factor known as the 
methyl-CpG binding proteins (MBPs) have been identified to bind methylated DNA in 
mammalian cells (Figure 1.4).  
In 1989, Dr. Adrian Bird identified and named the first MBP, MeCP2, after 
observing it binding to methylated CpG DNA sites.24 This early result prompted further 
characterization of the MeCP2 protein domain responsible for methylated DNA 
recognition, which was identified to encompass amino acids 78 to 162 and was termed 
the methyl-CpG binding domain (MBD)25-27 (Figure 1.4A). Once identified, homology 
searching with the MBD of MeCP2 led to the identification of multiple other MBD 
family proteins including MBD1 and MBD2 (Figure 1.4A).28-30 In addition to the MBD 
family of MBPs, two other main families have been identified including the structurally 
unrelated SET and RING associated domain (SRA) domain–containing proteins (UHRF1 
and UHRF2) and the zinc finger (ZF) family (ZBTB33, ZBTB4, and ZBTB38) (Figure 




















Figure 1.4.  The three families of mammalian MBPs. (A) The MBD family: MeCP2, 
MBD1, and MBD2. MBD, methyl-CpG binding domain; CXXC ZF, unmethylated-CpG 
binding zinc finger. (B) SRA domain proteins: UHRF1 (Ubiquitin-like with PHD and 
RING finger domains 1) and UHRF2. Ubl, ubiquitin-like domain; TTD, tandem tudor 
domain; PHD, plant homeodomain finger domain; SRA, SET and RING associated 
domain; RING, Really Interesting New Gene finger domain. (C) ZBTB33 (Zinc finger 
and BTB domain containing 33) and ZBTB33-like proteins: ZBTB4 and ZBTB38. 
BTB/POZ (Broad complex, Tramtrack, Bric a brac/Pox virus, and Zinc finger) domain; 
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The zinc finger family of MBPs  
The Bric-a-brac, Tramtrack, and Broad complex/Poxvirus and Zinc finger 
(BTB/POZ) domain proteins constitute a large family of transcription factors that share a 
well-known protein-protein interaction domain.31 ZBTB33 (also known as Kaiso) 
represents the founding member of the ZBTB MBP family. ZBTB33 was originally 
identified through its interaction with the Armadillo repeat containing protein p120-
catenin (p120ctn).32 ZBTB33 contains an N-terminal BTB/POZ protein-protein interaction 
domain and three C-terminally localized Kruppel-like Cys2His2 zinc fingers (ZFs) 
responsible for DNA binding (Figure 1.4C).  Homology searching with the Cys2His2 ZFs 
of ZBTB33 identified two other family members, ZBTB4 and ZBTB38, that have been 
confirmed to also be capable of binding methylated DNA (Figure 1.4C).33 In addition to 
methylated DNA recognition, ZBTB33 is unique among MBPs in that it additionally 
recognizes a sequence specific nonmethylated DNA target termed the Kaiso Binding Site 
(KBS; TCCTGCNA).34 
 
The role of ZBTB33 in cancer  
           A mounting number of studies indicate various roles of ZBTB33 transcriptional 
activities in cancer progression. Significantly increased survival rate was shown in 
ZBTB33 knockout mice prone to develop intestinal cancer, indicating an essential role 
for ZBTB33 in disease progression.35 Further, in a colon cancer cell line, ZBTB33 was 
observed to induce cell cycle attenuation through methyl-dependent repression of 
CDKN2A.36 Accordingly, a correlation between the increase of ZBTB33 cytoplasmic-to-




human breast cancer tissues.37-39 Together, these results imply that ZBTB33 modulates 
various cancer promoting biological pathways specific to different cancer type. However, 
currently there are no comprehensive mechanistic studies that describe how ZBTB33 
promotes and progresses the cancer state. 
 
Conclusion 
While sufficient evidence suggests that the ZBTB33 protein plays a role in 
cancer, an extensive analysis of the gene targets and signaling pathway regulated by this 
protein has yet to be extensively investigated. Thus, we attempted to establish the first 
complete list of genes targeted by ZBTB33, the methylation status of these genes, and the 
transcriptional outcomes of ZBTB33 occupation at these gene sites in cancer cell lines. 
This data provides initial important insights into how the bimodal DNA recognition by 
ZBTB33 mediates disease relevant transcription. 
With recent advancements in applied genomics and high-throughput screening 
methods, new powerful techniques have been developed for investigating global genomic 
protein-DNA interactions. One such technique couples chromatin immunoprecipitation 
with exonuclease digestion and next generation sequencing (ChIP-exo).40 While this 
technique is capable of mapping global DNA binding sites at single base pair resolution it 
also harbors numerous false positives, which reduces the ability to identify real binding 
targets for low occupancy transcription factors or for proteins in which the consensus-
binding site is not known.  
Thus, we designed a complementary method to generate a ChIP-exo specific input 




confidence level of real binding targets in these data sets.41 We show that this method 
allows for more accurate de novo motif discovery searching, which is important for high 
confidence identification of unknown transcription factor genomic binding sites.  We 
tested this method on a well-established protein CTCF in HeLa cells and demonstrated 
that its binding motif can be found unbiasedly throughout the genome with high 
confidence.  
Application of our improved ChIP-exo method for ZBTB33 revealed additional 
issues with ChIP-based techniques coupled with next-generation sequencing. In ChIP-
exo, we found that the lack of idealized lysine or cysteine cross-linking with guanosine 
bases limits the chances for stable protein DNA interactions between ZBTB33 and its 
cognate DNA sequence. Therefore, we suggest that the unsuccessful ZBTB33 ChIP-exo 
attempts were due to premature reverse cross-linking as a result of insufficient 
protein:DNA cross-linking strength and prolonged high temperature exposure during the 
ChIP-exo procedure. 
While ChIP-seq does not include high temperature steps that would compromise 
the protein-DNA cross-links, it also does not identify ZBTB33-specific genomic 
occupation sites. While the KBS and mCpG ZBTB33 targets can be detected through 
ChIP-PCR,42-45 ChIP-seq analysis appears to mainly enrich DNA motifs for other well-
known transcription factors such as CTCF.46 Thus, we hypothesize that ZBTB33 ChIP-
seq may only report on indirect protein:protein:DNA interactions. Surprisingly, we also 
observed that ChIP-qPCR analysis of the ChIP-seq samples after library preparation 
showed no genomic occupation of the sites observed prior to preparation of the library. 




occupation sites may also result from a loss of this information during one or more of the 
library preparation steps. 
Along with ChIP-based high-throughput sequencing methods, whole genome 
shotgun bisulfite sequencing and RNA sequencing (RNA-seq) are other powerful 
methodologies that inform on the global DNA methylation status and global 
transcriptome of a given cell, respectively. Combined, these techniques can be used to 
precisely determine the methylation status of genes and inform about transcriptional 
outcomes at a given gene target. By combining these methods we found mechanistic 
details for how ZBTB33 mediates cell-specific cell cycle regulation in a cancerous cell 
line. Specifically, it was determined that cell proliferation in HeLa cells is induced by 
direct activation of the cyclin D1 and cyclin E1 genes by ZBTB33. Activation of these 
genes leads to RB1 hyper-phosphorylation and increased E2F transcriptional activity, 
which facilitates G1- to S-phase transition. On the other hand in HEK293 cells ZBTB33 
indirect deactivation of cyclin E results in both decreased RB1 phosphorylation and E2F 
activity thus decelerating G1 transition. Therefore, we identified a novel mechanism by 
which ZBTB33 accelerates cancer cell proliferation through the cyclin D1/cyclin 
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PAtCh-Cap: INPUT STRATEGY FOR IMPROVING ANALYSIS  
OF ChIP-exo DATA SETS AND BEYOND 
 
Introduction 
  ChIP-seq (chromatin immunoprecipitation coupled with next-generation 
sequencing) has emerged as a powerful and widely used methodology for defining the 
site-specific localization of transcription factors and histone marks in the context of the 
cellular genome.1-3 Since inception of this core technique nearly a decade ago, several 
improvements have been implemented to expand the capabilities,4-11 reduce costs12,13 or 
maximize resolution.14-16 In many of the recently enhanced ChIP-based methods 
including ChIP-exo, ChIP-nexus, lobChIP and ChIPmentation,12-15 several steps of 
sample and/or library preparation are performed on bead-bound immunoprecipitated 
chromatin, posing a challenge in generating a similarly treated input control required for 
downstream bioinformatic analysis and data quality assessments.  
 Numerous reports have focused on the sources and methods for removal of 
artifacts in ChIP-based data sets, many of which highlight the necessity and critical 
importance of having a proper input control.2,17-22 For ChIP-seq, input controls are 
normally derived from isolated cellular DNA that has been cross-linked, sheared, and 
Reprinted (adapted) with permission from Terooatea, T. W.; Pozner, A.; Buck-Koehntop, 




ideally chemically treated in an analogous manner to DNA immunoprecipitated for the 
protein of interest. When subjected to high-throughput sequencing in parallel with the 
ChIP sample, the input control informs on the genomic locations of technique specific 
artifact peaks that exist in the ChIP-seq data set. As such, the use of an input control has 
become a core component of the communally agreed upon standards and guidelines for 
ChIP-seq experiments.20 In lieu of having a comparable input, less ideal methods for 
artifact removal must be implemented such as: 1) utilizing an IgG control, which 
typically pulls down comparably less DNA resulting in lower library complexity and 
significant sequencing biasing relative to the ChIP sample;19,20 2) relying on only filtering 
ChIP-seq derived blacklisted peaks, which is unable to eliminate technique specific false 
positives; and/or 3) applying alternative peak caller strategies in which p-values may 
provide less reliable false discovery rates (FDRs), reducing confidence in the statistical 
significance of identified peaks.22 Thus, a general procedure for producing a matched 
input control that can facilitate technique specific artifact removal would greatly increase 
the quality and confidence of information gained from the above listed modified ChIP-
based methodologies that perform additional bead-bound processing steps.12-15 
 Indeed, bioinformatics treatments commonly utilized in ChIP-seq data analysis, 
such as blacklist filtering and duplicate read removal, have proven to be inappropriate for 
eliminating artifacts in ChIP-exo data.17,23 It is understood that due to the narrow peak 
distributions observed in high-resolution methods such as ChIP-exo, removal of duplicate 
reads would discard essential peak information,17,23 whereas the failure of blacklisting to 
improve these data sets is likely a direct result of technique specific variances in artifact 




have variable artifact signatures.24 While methods like ChIP-exo15 and ChIP-nexus14 have 
undoubtedly increased resolution over standard ChIP-seq, the high number of washing 
and digestion steps in conjunction with decreased library complexity23 result in 
significant false positive peaks that can considerably impact downstream data analysis. 
This may be of minimal concern for histone proteins, high occupancy transcription 
factors, or transcription factors for which the consensus binding motif is well 
characterized. However, for analysis of transcription factors where the consensus 
sequence has yet to be identified, or for proteins that have a globally low genomic 
occupancy, the persistence of false positives in these data present a significant barrier in 
reliably identifying peaks with high confidence and discerning de novo binding motifs.  
 Here, we report a method for nonspecifically capturing cross-linked chromatin 
complexes via protein carboxylate groups that allows for the DNA to be subjected to all 
downstream chemical treatments in parallel with bead-bound chromatin separately 
immunoprecipitated for the target of interest. This input control method, termed protein 
attached chromatin capture (PAtCh-Cap), is designed to be facile and universally 
applicable to any of the current12-15 and future ChIP-based techniques that perform 
additional chemical and library preparation steps on bead-bound chromatin. Applying our 
input control method to the analysis of CTCF ChIP-exo data demonstrated that we were 
able to selectively remove artifacts in both pericentromeric and gene proximal regions, 
significantly increasing confidence in peak identification, revealing previously 
unidentifiable peaks and affording the capability of performing a de novo motif search 
analysis. This improved analysis capability within a high-resolution ChIP-exo data set 




independent cellular function.  
 
Materials and methods 
Cell culturing  
HeLa cells (from the laboratory of Prof. C. J. Burrows; University of Utah) were 
cultured in Dulbecco’s modified Eagle medium supplemented with 4.5 g/L glucose, 10% 
fetal bovine serum, and 2 mM glutamine and maintained in a humidified incubator at 37 
°C and 5% CO2. Cell counting and viability analysis was performed on a Countess 
Automated Cell Counter (Thermo Fisher Scientific). Cell line authentication to confirm 




For each of the two ChIP-exo replicates, 20 × 106 HeLa cells were fixed with 1% 
formaldehyde for 15 min to cross-link protein:DNA complexes, followed by a quench 
with 125 mM glycine. The IP, exonuclease digestions and library generation procedures 
were all performed using a commercially available ChIP-exo Kit (Active Motif) 
following the manufacturer's instructions with the few noted modifications. A Diagenode 
Bioruptor Standard sonication device (run at max amplitude for 5 × 15 min in ice water) 
was used to shear the cross-linked DNA to 100–400 bp fragments. Cell debris was 
removed by centrifugation and the supernatant containing the solubilized chromatin 
DNA:protein complexes were isolated. Prior to further treatment, 10% of the sheared 




(see PAtCh-Cap section below). For the IP step, protein G coated magnetic beads were 
prefunctionalized with CTCF antibody (Millipore) prior to incubation with the sheared 
chromatin sample. DNA purification after reverse cross-linking was performed with the 
MinElute PCR Purification Kit (Qiagen). It should be noted that the library preparations 
performed with the Active Motif ChIP-exo Kit are designed to be compatible with the 
Illumina sequencing platform.25 Final purified DNA libraries were sequenced by the 
High-Throughput Genomics Core within the University of Utah Huntsman Cancer 
Institute using the Illumina HiSeq 2000 platform. 
 
Protein attached chromatin capture (PAtCh-Cap) for ChIP-exo 
Following two series of washes with 0.01 M PBS (pH 7.4), 50 µg of M-280 
streptavidin coated Dynabeads (Thermo Fisher Scientific; equivalent to the number of 
beads utilized per reaction in the Active Motif ChIP-exo Kit) were conjugated with 10 µl 
of 50 nM EZ-link amine-PEG3-Biotin (Thermo Fisher Scientific; PEG = polyethylene 
glycol) in 0.01 M PBS (pH 7.4) at room temperature for 20 min. These beads were 
selected as they have the same size and core material composition as the protein G coated 
magnetic beads utilized in the Active Motif ChIP-exo Kit. The biotinylated beads were 
then washed twice with 0.01 M PBS (pH 7.4) and once with 0.1 mM MES (pH 5.0) to 
remove any nonconjugated material. For each of the two replicates, the input sample 
(obtained as discussed above) was combined with 300 µl of 0.1 M EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride) along with the prefunctionalized 
biotinylated magnetics beads and incubated in 10 ml 0.1 mM MES buffer (pH 5.0) for 3 h 




beads, the input samples were treated identically as described above for the CTCF ChIP-
exo samples utilizing reagents and materials from the Active Motif ChIP-exo Kit.  
 
Preparation of input DNA for ChIP-seq  
For each of the three replicates, 20 x 106 HeLa cells were fixed with 1% 
formaldehyde for 15 min to cross-link protein: DNA complexes, followed by a quench 
with 125 mM glycine. Cells were washed with cold 0.01 M PBS (pH 7.4) and lysed for 
10 min at 40 °C in cell lysis buffer (50 mM HEPES (pH 8.0), 140 mM NaCl, 1 mM 
EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100). Cellular nuclei were then 
washed (10 mM Tris-HCl (pH 8.0), 200mM EDTA), centrifuged and resuspended in 
nuclear lysis buffer (50 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM EDTA, 1% SDS).  
A Diagenode Bioruptor Standard sonication device (run at max amplitude for 5 x 15 min. 
in ice water) was used to shear the cross-linked DNA to 100 - 400 bp fragments. 
Proteinase K digestion was performed overnight at 55 °C. DNA was purified with the 
MinElute PCR Purification Kit (Qiagen). DNA quantification, library construction, and 
sequencing were all performed by the High-Throughput Genomics Core within the 
University of Utah Huntsman Cancer Institute. The input DNA libraries were sequenced 
using the Illumina HiSeq 2000 platform. 
 
RNA interference and RNA-seq  
HeLa cells were transfected with either a scrambled siRNA or one of two CTCF 
siRNAs (Thermo Fisher Scientific) in triplicate for each siRNA using Lipofectamine 




(pH 7.4) and resuspended in TRIzol (Thermo Fisher Scientific) prior to RNA extraction 
with the Direct-zol RNA Kit (Zymo Research). Prior to submission for high-throughput 
sequencing analysis, an aliquot of the RNA from each sample was reversed transcribed 
using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). 
The amount of CTCF was then determined in each sample by quantitative real-time PCR 
(qRT-PCR), utilizing HPRT1 as a normalization control, to ensure that sufficient CTCF 
knock-down was achieved. In parallel, protein was extracted from HeLa cells after 
siRNA transfection utilizing NP-40 buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1.0% 
NP-40) supplemented with protease inhibitors (Roche) and separated by gel 
electrophoresis. Proteins were then transferred to nitrocellulose membranes and 
immunoblotted using a CTCF antibody (Millipore) following standard procedures, to 
ensure sufficient knockdown was also achieved at the protein level. For RNAseq, RNA 
quality control measurements, purification, library construction, and sequencing were all 
performed by the High-Throughput Genomics Core within the University of Utah 
Huntsman Cancer Institute. In short, RNA quality was measured on a Bioanalyzer RNA 
6000 Nano Chip. Total RNA was then further purified with the RiboMinus Eukaryote Kit 
for RNA-seq (Thermo Fisher Scientific). Small and long directional RNA-seq libraries 
were then constructed using Illumina TruSeq Stranded mRNA Sample Prep with poly(A) 








Sequencing data analyses  
ChIP-exo fastq files were aligned to the human genome (hg19) using Novoalign 
(Novocraft, Inc.) and the following parameters: -0 SAM –r. Sam files were then sorted 
and indexed with SAMtools.26 Peak calling was performed with and without the input 
control by MACS227 using the following standard parameters: model fold settings of 5 to 
50 q-values with a cutoff of 0.05. Bedgraph outputs from MACS2 were viewed on the 
Integrated Genome Browser (IGB).28 The MACS2 bdgcmp command was further 
performed to obtain the read coverage tracks after ChIP-exo normalization to the PAtCh-
Cap derived input control. RNA-seq fastq files were similarly aligned to the human 
genome (hg19) using Novoalign (Novocraft, Inc.) and peak called with the USeq suite.21 
RNA-seq reads were aligned with all known and theoretical splice junctions using the 
following parameters: -r All 50 -t 40 -o SAM 90 –k. The USeq NovoalignParser 
application was then used to parse the alignment files into binary point data by setting the 
posterior probability to 0 and alignment score threshold to 60. The 
MultipleReplicaDefinedRegionScanseqs USeq application, which utilizes the DESeq R 
package,29 identified statistically significant differentially expressed genes between cells 
treated with the scrambled siRNA and CTCF depleted cells.  
 
Bioinformatics analyses  
 To identify the high confidence ChIP-exo peaks, the peak confidence level was 
plotted against the ranked peak number. Upon doing this, a clearly observable inflection 
point separated a subset of peaks with the highest intensity from the overall peaks 




enriched regions characterized by a –log(q-value) higher than the inflection point and a 
line with a slope of –tan 1 to the curve. Further, ChIP-seq input identified blacklisted 
genomic regions from the DAC, DER and UHS lists30 were intersected with the above 
determined high-confidence pools for both the CTCF ChIP-exo data with and without 
input treatment. The DAC and DER blacklisted regions were downloaded from the 
UCSC table browser (http: //hgwdev .cse. ucsc. edu/ cgi-bin /hg FileUi?db =hg19 &g= 
wgEncode Mapability)31 whereas the UHS regions were extracted from the following 
site: https://sites.google.com/site/anshulkundaje/projects/blacklists. 
 High confidence peaks were then subjected to de novo motif discovery analysis 
using RSAT32-34 with the following parameters: peak -motifs  -v 1 -title bedfile -i $RSAT 
-max_seq_len 200 -markov auto -disco oligos,positions,local_words -nmotifs 8 -minol 6 -
maxol 6 -no_merge_lengths -2str -origin center -motif_db jaspar_core_vertebrates. In 
addition to the expected CTCF consensus sequence, two additional motifs were identified 
from the de novo motif analysis in the input treated ChIP-exo data. FIMO35 was then 
used to identify matches for all of these motifs in all peak regions (‘fimo -bgfile 
flanking.bg–motif 1 motif.meme.txt) with a default p-value threshold of 10-4. To 
determine the preferential spacing and co-localization of the additionally identified motifs 
relative to the CTCF consensus sequence, the CTCF core motif was extended by ±30 
nucleotides and analyzed by SpaMo (spamo -png -bgfile -dumpseqs -inc 1 
meme.motif.txt).36 Average logos representing all the extended motifs around the 
centralized CTCF consensus were created using MEME.37 The read tag and nucleotide 
base heatmaps as well as aggregate plots were generated using in-house python scripts. 




and centered at their CTCF core motifs using the USeq scoreSequences application. All 
instances in which the identified CTCF motifs were localized within gene promoters 
(defined as +/-1000 bps around the transcription start site (TSS)) were intersected with 
the genes identified to be differentially expressed from the above RNA-seq analysis (0.05 
adjusted Benjamini–Hochberg p-value). For each set of filtered differentially expressed 
genes, Ingenuity Pathway Analysis (IPA, www.ingenuity.com) was performed to identify 
uniquely significant biological pathways correlated with each motif. 
 
Results and discussion 
Development of a method for nonspecific protein mediated chromatin capture 
Development of a general method to generate matched input controls for ChIP-
based techniques that perform additional preparation steps on bead-bound 
immunoprecipitated chromatin complexes required that two major challenges be 
addressed. First, it was necessary to identify a way to nonspecifically pull-down a 
random sampling of cross-linked chromatin complexes that could be affixed to magnetic 
beads with a sufficient affinity to remain associated throughout the following treatment 
steps. Second, it was ideal to determine a strategy for affixing these chromatin complexes 
to the magnetic beads via the proteins, leaving the chromatin DNA accessible for further 
processing. These criteria eliminated the possibility of utilizing an antibody based 
approach as no single protein-specific antibody would be capable of immunoprecipitating 
a completely unbiased background representation of the chromatin complexes in a given 
sample with adequate affinity. 




complexes, we took advantage of the readily available amine functionalized pegylated 
biotin reagents commonly utilized for the conjugation of EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride) activated protein carboxylates. In 
short, after standard cross-linking, chromatin isolation and DNA shearing procedures, an 
aliquot of the sample (typically 10%) is removed to generate the input control. In parallel, 
streptavidin coated magnetic beads are conjugated with an amine functionalized 
pegylated biotin (amine-PEG3-biotin). These preconjugated beads are then incubated 
with the isolated cross-linked chromatin complexes in the presence of EDC producing 
bead-bound chromatin complexes covalently linked via protein carboxylate groups 
(Figure 2.1). These pulled-down complexes can then be subjected to additional chemical 
processing steps in parallel with bead-bound chromatin separately immunoprecipitated 
for the target of interest. Compared to other chromatin capture methods that pull-down on 
modified DNA,38,39 which may result in disruption of protein:DNA interactions prior to 
cross-linking and/or mask accessibility of the chromatin fragments, our PAtCh-Cap 
method achieves the goal of nonspecifically pulling-down chromatin bound proteins, 
leaving the cross-linked DNA freely accessible for additional treatments. 
 
Application of PAtCh-Cap to generate an input control for technique  
specific artifact removal in ChIP-exo data 
 As a proof-of-principle, we applied our PAtCh-Cap strategy to produce a ChIP-
exo input control that could be utilized in downstream bioinformatics analysis of CTCF 
genomic occupations in HeLa cells. After cross-linking and shearing, 10% of the  










Figure 2.1. Schematic overview for the protein attached chromatin capture (PAtCh-Cap). 
Streptavidin coated magnetic beads are first conjugated with amine-PEG3-biotin (where 
PEG is polyethylene glycol). After standard cross-linking, chromatin isolation and DNA 
shearing procedures, 10% of the sample volume is removed and incubated with the 
preconjugated beads in the presence of EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride). EDC reacts with protein carboxylate 
groups, forming unstable o-acylisourea activated esters that can undergo nucleophilic 
attack by the primary amines on the amine-PEG3-biotin prosthetics. This forms a 
covalent amide linkage with proteins in the chromatin complexes and releases an isourea 
by-product. Once bead-bound, these chromatin complexes can be subjected to additional 
chemical processing steps in parallel with bead-bound chromatin that was separately 









the PAtCh-Cap method, generating the bead-bound input control as described above. In 
parallel, protein G coated magnetic beads were conjugated with CTCF antibody and 
utilized to selectively immunoprecipitate CTCF-bound chromatin fragments from 
theremaining cross-linked chromatin complex pool. At this stage, both the bead-bound 
input control and isolated CTCF-containing chromatin complexes were simultaneously 
and identically subjected to all subsequent exonuclease digestions, library preparation 
steps, reverse cross-linking, purification procedures, quality assessments, and high-
throughput sequencing. 
To assess whether the use of sequencing data from a similarly treated input 
control was able to sufficiently remove artifacts and improve peak identification within 
our CTCF ChIP-exo data set, we first defined pools of high-confidence peaks from this 
data with and without input treatment. These high-confidence pools were defined from 
enriched regions by plotting the -log(q-value) versus the ranked peak number and only 
considering peaks above the inflection point and a line with the slope of –tan 1 to the 
curve (Figure 2.2A). Once identified, the high-confidence peaks from the pools with and 
without input treatment were intersected and found to have a high degree of overlap, 
though in each case there were also a significant number of peaks that were individual to 
each pool (Figure 2.2B). To discern whether artifact peaks were eliminated from the 
ChIP-exo data set, we first performed a weight matrix search21 for the core CTCF motif 
within each set of high-confidence peaks. This search revealed an approximate 20% 
increase in peaks containing the CTCF motif out of total high-confidence peaks called for 















Figure 2.2. Application of PAtCh-Cap to CTCF ChIP-exo data allowed for significant 
artifact removal and improved confidence in peak identification. (A) To identify high-
confidence CTCF peaks, all peaks called with a 0.05 q-value threshold from the ChIP-
exo data with (red) and without (black) input treatment were plotted as the –log(q-value) 
versus ranked peak number. High confidence peaks were determined to be those 
characterized by a –log(q-value) higher than the inflection point and a line with a slope of 
–tan 1 to the curve (denoted by vertical lines). (B) Venn diagram demonstrating the 
overlap of high-confidence peaks identified from data sets with and without input 
treatment (top). The number of CTCF motifs found within each pool is denoted and 
clearly shows that the percentage of CTCF containing peaks relative to the total increases 
substantially after input treatment. Venn diagrams for the overlap of blacklisted peaks 








remaining peaks that do not harbor the core CTCF motif in the cleaned ChIP-exo data 
likely represent genomic occupations for the numerous CTCF protein interacting 
partners.40 Together, these findings indicate that bioinformatic treatment of the CTCF 
ChIP-exo data with the input control not only removes a significant number of artifact 
peaks but also allowed for identification of additional CTCF-containing peaks that were 
otherwise masked. 
As further confirmation, we separately intersected known ChIP-seq blacklisted 
peaks with the above determined high-confidence pools for the CTCF ChIP-exo data with  
and without input treatment. Blacklisted peaks constitute known genomic artifact regions 
systematically observed in input controls from standard ChIP-seq data and it has become 
an acceptable practice to exclude these reads out of ChIP-seq data sets.30,41–43 As can be 
seen in Figure 2.2B, nearly all of the blacklisted peaks are present in the pool of ChIP-
exo peaks excluded by the input control treatment. This clearly demonstrates that the 
majority of these blacklisted peaks are captured by the ChIP-exo input control and that as 
previously observed, the removal of blacklisted peaks alone is not sufficient to remove all 
ChIP-exo specific artifacts.17   
 Furthermore, we prepared a ChIP-seq input control from our HeLa cells and 
compared this with our ChIP-exo input. Comparisons of enrichment profiles and genome-
wide correlation analysis between these input controls demonstrates that there are a 
number of artifact peaks that are common between the two methods, though there are 
many more ChIP-exo specific false positives (Figure 2.3A (green loci) and Figure 2.3B). 
Indeed, intersection of the identified peaks in the ChIP-seq and ChIP-exo input controls 








Figure 2.3. Technique specific removal of false positive peaks in ChIP-exo data. (A) 
Color-coded heat map enrichment profiles visualized within the Integrated Genome 
Browser (IGB) for the standard ChIP-seq input, the bead-bound ChIP-exo input, and the 
ChIP-exo profiles without and with input treatment mapped onto chromosome 1. (B) 
Genome-wide correlations (1,000 bp windows) for standard ChIP-seq inputs compared to 
the bead-bound ChIP-exo inputs in HeLa cells. (C) Venn diagram showing the intersect 
of peaks (gray) within the standard ChIP-seq input (not observable) and the ChIP-exo 








control (Figure 2.3C). Additionally, example read coverage tracks of CTCF ChIP-exo 
with and without input treatment indicate that use of the input control dramatically cleans 
up artifacts not only within pericentromeric, but also gene proximal regions (Figure 2.4). 
Analysis of genomic sequences underneath the peaks removed by the ChIP-exo input 
determined that these sites do not contain the CTCF motif, whereas remaining peaks do.  
 Finally, we sought to determine whether the increased incidence of artifact peaks 
in the ChIP-exo data was a consequence of biasing from the exonuclease digestion or GC 
content during sequencing. Comparative analysis of the nucleotide frequency and GC 
content plots from the ChIP-exo input controls and CTCF ChIP-exo sequencing data 
relative to standard ChIP-seq input controls indicates that there is a minor biasing 
common between all of the ChIP-exo data sets that likely results from the exonucleases 
used in the processing of these samples (Figure 2.5). Nonetheless, this observed 
exonuclease biasing in the ChIP-exo samples is not sufficient to account for the 
significant increase in generated artifacts relative to ChIP-seq data sets. Thus, it is likely 
that the remainder of these artifacts result from nonspecific interactions that occur during 
the additional processing steps performed on the bead-bound chromatin samples. This 
further suggests that the other bead-bound ChIP-based methods12-14 may also generate 
an increase in technique specific artifacts relative to standard ChIP-seq and that a strategy 
such as PAtCh-Cap to produce a matched input is needed. Together all of the above 
findings clearly demonstrate that ChIP-exo data sets harbor significant technique specific 
false positive peaks and that our PAtCh-Cap method was not only able to remove these 
artifacts, but also improved confidence in peak identification. 









Figure 2.4. Representative CTCF ChIP-exo read coverage tracks for the pericentromeric 
region of chromosome 1. (A) and the promoter of the KCNJ3 gene (B). The CTCF reads 
(blue) were normalized to the reads from the input control (green) using MACS227 to 
generate the enrichment read coverage tracks (red). Peaks identified by the MACS2 peak 
caller (represented in the bed tracks) are denoted as red or blue vertical lines for the 
CTCF ChIP-exo data sets with and without input treatment, respectively. Analysis of the 
genomic sequences underneath the remaining peaks after input treatment (vertical red 
lines) definitively showed that these sites contain the core CTCF motif as evidenced by 





Figure 2.5. FastQC  analysis for the ChIP-exo input, CTCF ChIP-exo, and ChIP-seq 
input replicates. (A) FastQC plots of nucleotide frequency as a function of base position 
for the ChIP-exo input, CTCF ChIP-exo, and ChIP-seq input replicates. The four colors 
represent the bases A (green), T (red), G (black) or C (blue). (B) FastQC plots showing 
that the GC count per read (red) for each ChIP-exo input, CTCF ChIP-exo, and ChIP-seq 








input control can dramatically improve artifact removal in ChIP-exo data, new 
bioinformatics tools will need to be developed that are capable of implementing input 
treatments while maintaining full resolution of ChIP-exo data sets. For the analysis 
presented here, we utilized the MACS2 peak caller26 as it has the built-in capability of 
determining peak enrichment over input controls and using local statistics to reduce 
biasing and calculate empirical FDRs. However, peak calling is administered by 
performing read-shifting to account for the offset in forward and reverse strand reads. In 
contrast, peak callers specifically designed for analysis of ChIP-exo data sets, such as 
GeneTrack41 or MACE,42 rely on retention of strand information by using 5’ cross-link 
borders on each strand to define “peak-pairs” that result in identification of high-
resolution protein footprints.23 Currently, neither of these ChIP-exo specific peak callers 
are capable of readily normalizing these data sets to input controls. Thus, it would be 
ideal to have a peak caller suite that can normalize the data relative to an input control 
without compromising resolution by eliminating strand information. 
 
Improved ChIP-exo data analysis identified a novel CTCF binding site 
 Once peaks within the high-confidence pools for the ChIP-exo data with and 
without input treatment were identified as described above (Figure 2.2A), we subjected 
each pool to a de novo motif search analysis.32-34 This search returned not only the core 
CTCF motif, but also its previously characterized flanking 5ʹ-site15,43 for both the 
untreated and input treated ChIP-exo CTCF data sets (Figure 2.6A). It has been shown 
previously that depending on the genomic occupation context, various combinations of 




















Figure 2.6. De novo motif search analysis. (A) Results for the de novo motif search 
analysis performed by RSAT on the highconfidence CTCF peaks identified from the 
ChIP-exo data without and with input treatment (refer to Figure 2A). The newly 
identified motif is only observed from the de novo search conducted on the input treated 
highconfidence pool. (B) Venn diagram from Figure 2B showing the overlap of high-
confidence peaks identified from data sets with and without input treatment (top). 
Distribution analysis of the newly identified CTCF motif within each of these pools 
(color coded numbers; bottom) clearly shows that this sequence is found nearly 
exclusively within the population of high-confidence peaks that were only identified after 
input treatment (blue). Enrichment profiles depicting CTCF genomic localizations 
represented by both aggregate plots and heat maps (left panels in Figure 2.7A and 2.7D) 
also confirmed CTCF occupancy at all sites identified within the input treated ChIP-exo 
data set identified from the de novo search, including the new consensus site which was 
found to be localized 2-4 base pairs 3’ of the CTCF core (Figure 2.7A and 2.7D). In 






conserved 5ʹ- and 3ʹ-flanking regions.15,43 This modularity in CTCF motif recognition is 
believed to allow for tunability in strength of the DNA binding interaction and 
subsequently chromatin residence time.43 Surprisingly, we also identified a novel 
consensus site in the de novo motif search, but only for the CTCF data set in which the 
input control was utilized (Figure 2.6A). This observation was confirmed by the fact that 
the peaks containing this new motif were nearly all localized within the high-confidence 
peak population that was only identified after input treatment of the ChIP-exo data 
(Figure 2.6B). Thus, identification of this novel motif was only possible when the ChIP-
exo specific artifact peaks were removed prior to de novo motif analysis. 
 Next, a comprehensive weight matrix analysis was performed to identify all peaks 
containing the core CTCF sequence within the complete input treated CTCF ChIP-exo 
data set, which resulted in 19,950 hits. To validate that all sequences found in the de novo 
motif search (Figure 2.7A) were localized proximal to the core CTCF site, a spaced motif 
analysis (SpaMo) was used.36 This search demonstrated that there was a significantly 
enriched spacing between the CTCF motif and the other two conserved sequences. 
 To determine the biological relevance of this newly identified 3ʹ-flanking 
sequence, we analyzed RNA-seq data from CTCF depleted HeLa cells. CTCF depletion 
was confirmed by both immunoblot and qRT-PCR (Figure 2.8). In the absence of CTCF, 
a substantial number of genes showed a significant transcriptional alteration relative to 
the control (Figure 2.9). Independent intersection of these altered genes with the CTCF 
ChIP-exo data with and without input treatment showed that many more promoter 
proximal peaks overlapped within the untreated ChIP-exo data set (Table 2.1). However, 










Figure 2.7. From the input treated CTCF ChIP-exo data set, (A) read tag distributions 
around all genomic CTCF-bound sites shown in the four binned motif combinations 
(right panel) were centered on the midpoint of the CTCF consensus to generate a heat 
map (top left),which is summed below as an aggregate plot. Denoted in blue and red are 
the sense and antisense strand read enrichments around the core CTCF motif, 
respectively. The centralized CTCF core sequence and adjacent motifs are depicted above 
a color map representation of 50 bp DNA stretches containing the various motif 
combinations (right panel). (B) Heat maps from RNA-seq data depicting gene transcripts 
exhibiting a two-fold up- (green) or down-regulation (red) after CTCF depletion relative 
to the scrambled siRNA control (Scr). For each motif group, CTCF promoter occupation 
sites (defined as ±1000 bps around the transcription start site (TSS)) were intersected 
with the RNA-seq data and resulting altered gene sets were binned as individual heat 
maps. (C) Each gene set from (B) was subjected to Ingenuity Pathway Analysis (IPA, 
www.ingenuity.com) to identify biological pathways uniquely modulated by each of the 
CTCF motif combinations. (D–F) The same analyses in (A–C) were performed separately 
















































Figure 2.8. Assessment of CTCF depletion via RNA interference in HeLa cells. (A) 
Representative immunoblot indicating CTCF protein depletion after HeLa cells were 
treaed with two different siRNAs relative to a scrambled siRNA (Scr) control. (B) 
Sufficient CTCF depletion at the mRNA level in HeLa cells was further confirmed by 
qRT-PCR. mRNA levels are represented as the fold CT change relative to HPRT1 and a 









































Figure 2.9. RNA-seq analysis after CTCF depletion in HeLa cells. (A) Genome-wide 
correlations (1,000 bp window) of the RNA-seq data acquired for each of the scrambled 
and CTCF siRNA replicates. (B) Comprehensive heat map from the RNA-seq data 
depicting gene transcripts exhibiting a two-fold up- (green) or down-regulation (red) after 













Table 2.1. Incidence of CTCF motif within ±1000 bps of regulated gene promoter TSS 
 
 CTCF ChIP-exo CTCF ChIP-exo Input 
Treated 
Total genes altered after CTCF 
depletion (from RNA-seq)  
1127 
Number of ChIP-exo peaks 
intersected with above altered 
genes 
771 448 
Number of intersected peaks 
containing core CTCF motif 
within promoter 
398 396 
















the input treated data set. Thus, the percentage of real peaks containing the CTCF core 
localized within promoters of regulated genes was improved >30% after input treatment. 
This analysis highlights the importance and necessity for being able to remove technique 
specific artifacts from ChIP-exo data sets and further demonstrates that our PAtCh-Cap 
derived ChIP-exo input control is able to perform this task remarkably well. 
In the context of the input treated CTCF ChIP-exo data, analysis of the altered 
genes binned by the various motif combinations denoted in Figure 2.7A and 2.7D showed 
that there was a clear set of transcriptional alterations that were specific to each of these 
bins, including the core CTCF consensus in conjunction with the newly identified 3ʹ-site 
(Figure 2.7B and 2.7E). As further evidence, analysis of the biological pathways 
associated with each of the binned gene sets demonstrated that several pathways were 
uniquely regulated by this newly identified extended CTCF motif (Figure 2.7C and 2.7F).  
While this analysis is not able to delineate direct versus indirect transcriptional regulation 
by CTCF, it does establish that CTCF occupation at sites containing the CTCF core in 
conjunction with the newly identified 3ʹ -flanking sequences independently modulates the 
transcriptional outcome of certain genes. 
 Here we have provided a simple and convenient method for generating technique 
specific input controls that affords increased confidence in peak identification and the 
ability to perform de novo motif searches for ChIP-based methods that utilize additional 
bead-bound processing steps. We anticipate that the presented PAtCh-Cap input control 
strategy will remove a barrier preventing advanced bead-bound ChIP-based techniques 
such as ChIP-exo from becoming mainstream, allowing them to be accessible to a 




biological questions. Indeed, using our approach afforded identification of a novel-
binding motif for the very well characterized protein CTCF that appears to have an 
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LIMITATIONS OF CURRENT ChIP AND HIGH-THROUGHPUT 
SEQUENCING TECHNIQUES TO INVESTIGATE ZBTB33 
GLOBAL GENOMIC OCCUPATIONS 
 
Introduction 
Numerous studies have shown that in cell, ZBTB33 (also known as Kaiso) binds 
both methylated CpG DNA sites and a sequence specific unmethylated DNA target, 
termed the Kaiso binding site (KBS).1-6 However, a recent high-throughput ChIP-seq 
study of ZBTB33 genomic occupancy contradicted these findings.7 Namely, ZBTB33 
ChIP-seq analyses in two hematopoietic cell lines (GM12878 and K562) showed 
preferential binding to an unmethylated palindromic DNA sequence TCTCGCGAGA 
and to several known transcription factor binding motifs.7 The inconsistency between the 
various studies demonstrating physiological ZBTB33 functions upon binding to 
methylated CpG and KBS and the observed ZBTB33 genomic occupations determined 
by the above mentioned ChIP-seq study highlight potential limitations in this method. It 
was thus thought that the low signal to noise ratio and low base pair resolution limitation 
of ChIP-seq may have reduced accurate detection of the minimal methylated ZBTB33 




a higher resolution high-throughput sequencing technique, would be valuable in mapping 
the global in cell ZBTB33 DNA occupancy sites and more specifically define the 
methylated DNA recognition motif.  
Unlike ChIP-seq, ChIP-exo is able to locate transcription factor DNA binding 
motifs with single base pair precision. However, due to the lack of appropriate input 
control for removing persisting background signals specific to ChIP-exo, the method 
produces disproportionately far too many false positives making it disadvantageous for 
studying low occupancy transcription factors and transcription factors for which the 
recognition motif is not yet well defined, such as ZBTB33. For that reason, we developed 
a novel method termed PAtCh-Cap (Protein Attached Chromatin Capture), that generates 
a specific input control which significantly reduces false positives, increases confidence 
in peak identification and affords de novo motif searching analysis.9 
Nonetheless, application of our new PAtCh-Cap method to ChIP-exo analysis of 
ZBTB33 in HeLa cells failed to identify ZBTB33-specific genomic occupations. Further 
investigations revealed fundamental issues regarding the ChIP step specific for proteins 
such as ZBTB33. First, it has been shown that the strength of the DNA:protein interaction 
after formaldehyde cross-linking varies dramatically from one transcription factor to 
another. Indeed, recent studies have demonstrated that the strongest covalent cross-
linkage occurs between lysine primary amines and guanine bases.10 Analysis of the 
structure of ZBTB33 in complex with its cognate methylated and KBS DNA targets 
showed that it does not have a binding interface lysine capable of forming such ideal 
cross-linking interactions.11 Furthermore, it has been shown that the reversal of 




This is significant as the ChIP-exo protocol includes several high temperature incubation 
steps capable of reversing these cross-links. Therefore, we suggest that the unsuccessful 
ZBTB33 ChIP-exo attempts were due to premature reverse cross-linking as a result of 
insufficient protein:DNA cross-linking strength and prolonged high temperature exposure 
during the ChIP-exo procedure. 
Unfortunately, applying the ChIP-seq technique to identify ZBTB33 global 
genomic occupation did not produce better results. Although this method does not 
include high temperature steps that would compromise the cross-link, as discussed above, 
it is unable to identify ZBTB33 specific genomic occupation sites. While the KBS and 
mCpG ZBTB33 targets can be detected through ChIP-qPCR,3-4 ChIP-seq analysis 
appears to mainly enrich DNA motifs for other well-known transcription factors such as 
CTCF.7 Thus, we hypothesize that ZBTB33 ChIP-seq may only report on indirect 
protein:protein:DNA interactions. Here we detail our efforts to identify the reasons for 
why ChIP-based methods do not work for transcription factors such as ZBTB33. 
 
Materials and methods 
 
Cell culturing  
HeLa cells were cultured in DMEM supplemented with 4.5 g/L glucose, 2 mM 
glutamine, and 10% FBS and maintained at 37 °C under 5% CO2. Cell counting and 
viability analysis was performed on a Countess Automated Cell Counter (Thermo Fisher 






Construction of Ad-ZBTB33-ZBTB33-HA vector and adenovirus infection 
 of HeLa cells 
The ZBTB33 open reading frame (ORF), obtained from GenScript, was fused to a 
C-terminal HA-tag and transferred into the pcDNA3.1 mammalian expression 
vector (Thermo Fisher Scientific) utilizing standard cloning strategies. To 
put ZBTB33 under control of its endogenous promoter, the original CMV promoter was 
replaced with a DNA fragment PCR-amplified from genomic human DNA encompassing 
2 kb of DNA upstream of the ZBTB33 transcription start site (TSS). Construction of 
the Ad-ZBTB33-HA vector and the viral lysate was prepared and titered by SignaGen 
Laboratories. HeLa cell monolayers were infected with the Ad-ZBTB33-HA construct at 
a multiplicity of infection (MOI) of 10 infectious units per cell for 16 h prior to 
preparation for additional experiments.  
 
ChIP-seq of ZBTB33 in HeLa cells 
For each duplicate, 20 x 106 HeLa cells with or without infection with the Ad-
ZBTB33-HA vector, were fixed with 1% formaldehyde for 15 min to cross-link the 
protein:DNA complexes, followed by a quench with 125 mM glycine. Cells were washed 
with cold PBS (pH 7.4) and lysed for 10 min at 40 °C in cell lysis buffer (50 mM HEPES 
(pH 8.0), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-
100). Cellular nuclei were then washed (10 mM Tris-HCl (pH 8.0), 200mM EDTA), 
centrifuged and resuspended in nuclear lysis buffer (50 mM Tris-HCl (pH 8.0), 100 mM 
NaCl, 10 mM EDTA, 1% SDS).  A Diagenode Bioruptor Standard sonication device (run 




100-400 bp fragments. Cell debris was pelleted by centrifugation and supernatant 
containing the solubilized chromatin protein:DNA complexes were isolated. Prior to 
further treatment, 1% of the sheared chromatin sample volume was removed from each 
replicate for input sample preparation. For the IP step, Protein G coated magnetic beads 
were prefunctionalized with either ZBTB33 (6F8, Santa Cruz) or HA-tag antibodies prior 
to incubation with the sheared chromatin sample. Proteinase K digestion was performed 
overnight at 55 °C. DNA was purified with the MinElute PCR Purification Kit (Qiagen). 
DNA quantification, library construction, and sequencing using the Illumina HiSeq 2000 
platform were all performed by the High-Throughput Genomics Core within the 
University of Utah Huntsman Cancer Institute.  
 
Bioinformatics analyses  
ChIP-seq fastq files were aligned to the human genome (hg19) using Novoalign 
(Novocraft, Inc.) and the following parameters: -0 SAM –r. Sam files were then sorted 
and indexed with SAMtools.13 Peak calling was performed by MACS214 using the 
following standard parameters: model fold settings of 5 to 50 q-values with a cutoff of 
0.05. Bedgraph outputs from MACS2 were viewed in the Integrated Genome Browser 




HeLa cells were cross-link treated and chromatin was sheared as described above 




(IP) reaction procedures were performed using materials from the Zymo-Spin ChIP Kit 
(Zymo Research) following the manufacturer’s instructions. The IP was carried out using 
an antibody against ZBTB33 (6F8, Santa Cruz). After quantitating the amount of 
genomic DNA (PicoGreen assay), equal amounts of ChIP amplicons for each sample 
were prepared with the SYBR Green Real-Time PCR Master Mix (Thermo Fisher 
Scientific) and analyzed by qPCR on a QuantStudio 6 Flex Real-Time PCR System 
(Thermo Fisher Scientific). The fold enrichment was determined based on the cycle 
differences after normalization to input DNA. A region from the ELL3 gene was 
amplified as a negative control.  
 
Co-immunoprecipitation 
HeLa cells were collected in ice-cold PBS and lysed in nondenaturing RIPA 
buffer (10 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% 
sodium deoxycholic acid, and 5 mM EDTA) supplemented with an EDTA-free protease 
inhibitor cocktail (Roche). Protein lysates were cross-linked with dimethyl pimelimidate 
and incubated overnight at 4 °C with Protein G Dynabeads (Thermo Fisher Scientific) 
preconjugated with an antiZBTB33 antibody (6F8, Santa Cruz). Adequately washed 
bound material was subsequently eluted with 50 mM glycine (pH 2.8) and boiled for 10 
min. Eluates were separated by gel electrophoresis, transferred to nitrocellulose 
membrane, and immunoblotted with ZBTB33 (Santa Cruz), CTCF (Millipore), or PARP1 






Results and discussion 
Failure of ChIP-exo for analysis of ZBTB33 genomic occupations 
The need for a high-resolution technique to identify minimal global ZBTB33 
methylated CpG recognition sites within CpG islands suggested that ChIP-exo would be 
the ideal method. To achieve this level of resolution, the ChIP-exo method utilizes a 
lambda exonuclease to digest unprotected DNA around cross-linked protein:DNA 
complexes to map the protein binding DNA footprint.8 Consequently, the nuclease 
digestion of background DNA yields high signal to noise ratio peaks. Thus, we utilized 
ChIP-exo in conjunction with our newly developed PAtCh-Cap method9 to determine the 
genome-wide binding occupancies of ZBTB33. However, after ChIP-exo, high-
throughput sequencing and extensive bioinformatics analysis, we observed only artifact 
peaks and no incidence of ZBTB33-specific genomic occupations. This outcome led us to 
further investigate why this method failed for ZBTB33.  
One major way in which the ChIP-exo procedure differs from standard ChIP-
seq16,17 is that there are several chemical processing steps that occur on bead-bound 
chromatin samples, each of which requires incubation of the samples at higher 
temperatures ranging from 25 – 37 °C for up to 5 h. Recent reports have demonstrated 
that reversal of formaldehyde cross-links between protein and DNA is temperature 
dependent (Figure 3.1).12 Further, there are only a couple of specific amino 
acid:nucleotide interactions that result in strong formaldehyde generated cross-linking 
interactions, with linkages between lysine and guanosine bases being the strongest 














Figure 3.1. Temperature dependence of the formaldehyde mediated protein:DNA cross-
link reversal rates. The percentage of protein-free DNA measured by qPCR is plotted 
versus time for samples at four different temperatures: 4, 23, 37, and 47 °C. The error 
bars are the standard deviation of qPCR signals. A best fit linear regression is shown for 



































Figure 3.2. Time dependent formation of cross-links between amino acids and 
nucleosides after formaldehyde treatment. Formation of cross-links between 4 mM amino 
acids and 4 mM nucleosides treated with 50 mM formaldehyde at various times. , sum 
of Lys products; , Cys-CH2-dG; ▲, Cys-CH2-dA; , Cys-CH2-dC; , His-CH2-dA; 
and , Trp-CH2-dG. Relative yields are based on integration of HPLC peak areas in UV 










 Thus, we utilized the high-resolution structure of ZBTB33 bound to both its 
methylated and sequence-specific unmethylated DNA targets11 to determine whether 
ZBTB33 has the ability to form the strongest lysine:guanine cross-links (Figure 3.3). As 
suspected, ZBTB33 is not capable of forming these strong formaldehyde cross-links. 
Similar analyses on well-known protein structures with successful ChIP-exo and ChIP-
seq data sets reveals that they all are able to make these idealized lysine:guanosine 
formaldehyde cross-links.8 Thus, it is likely that the inability of ZBTB33 to form these 
strong cross-links with its DNA targets makes it susceptible to premature cross-link 
reversal caused by the numerous high temperature incubation steps in the ChIP-exo 
procedure, resulting in a loss of the ZBTB33-specific genomic occupation sites. 
 
Additional issues with analysis of ZBTB33 genomic occupations by ChIP-seq 
 The discrepancies between various reports on the physiological functions of 
ZBTB33 mediated by both in cell KBS and methyl-CpG site recognition and the 
observed lack of genomic occupations at these sites by ChIP-seq led us to investigate this 
further. More specifically, while ChIP-qPCR studies report that ZBTB33 binds to 
methylated DNA and KBS sequences3-4 ChIP-seq data from two cell lines (GM12878 and 
K562) showed only preferential bindings to an unmethylated palindromic DNA sequence 
TCTCGCGAGA and several sequences belonging to other transcription factors (Figure 
3.4).7 Thus, we sought to evaluate whether these inconsistencies originated from 
differences in the cell lines used or the quality of the ChIP-grade ZBTB33 antibody. 
To address these questions, we performed ChIP-seq in another cell line (HeLa) 













Figure 3.3. Crystal structures of ZBTB33 in complex with both its methylated and 
sequence specifc nonmethylated DNA targets. Crystal structures of ZBTB33 in complex 
with both its cognate methylated CpG (dark protein colors, light blue DNA) and the KBS 
sequence (light protein colors, yellow DNA). These structures highlight the lack of lysine 
and cysteine residues at the DNA binding interface capable of cross-linking with a 































Figure 3.4. Motif analyses of cell type-specific ZBTB33 (Kaiso) binding sites. ZBTB33 
peaks from GM12878 and K562 were compared to identify common and cell type-
specific binding sites (the median tag height is shown in parentheses). GM12878- and 
K562-unique peaks were divided into two sets of peaks, those that contain and those that 
lack a ZBTB33 motif; GM12878-unique peaks were further separated into promoter 
proximal and promoter distal sets. A motif analysis was then performed for each set of 
peaks, identifying motifs for the GATA and CTCF families of transcription factors in the 
K562-unique peaks and motifs for the ETS and Runt families of transcription factors in 






antibody to IP endogenous ZBTB33 or an HA ChIP-grade antibody to IP C-terminally 
tagged ZBTB33 (ZBTB33-HA). Once prepared, we first utilized ChIP-qPCR to analyze 
whether ZBTB33 occupied known target sites prior to submitting these samples for 
library preparation and high-throughput sequencing. Similar to previous reports,1,3  
ZBTB33 clearly demonstrated genomic occupations at both KBS and methylated-CpG 
containing DNA sites (Figure 3.5A).  
Nonetheless, ChIP-seq analysis on these same samples demonstrated that the 
ChIP-seq results with both endogenous and HA-tagged ZBTB33 recapitulated previously 
reported findings (Figure 3.6),7 indicating that the ZBTB33 ChIP-grade antibody does not 
participate in a high level of nonspecific interactions and that the lack of KBS and 
methyl-CpG occupation is not cell type specific. Surprisingly, ChIP-qPCR analysis of the 
ChIP-seq samples after library preparation showed that there was no longer genomic 
occupation of the sites observed prior to preparation of the library (Figure 3.6B). This 
finding is significant and suggests that the inability to identify ZBTB33 genomic 
occupation sites may result from a loss of this information during one or more of the 
library preparation steps. 
 It is worth noting that unlike ChIP-exo, all of the ChIP-seq data sets for ZBTB33 
clearly show highly enriched occupation sites within numerous genes. Yet, advanced de 
novo motif searches within these data sets do not identify known ZBTB33 DNA targets.7 
Intriguingly, these motif-searching analyses do identify consensus sequences for the 
known ZBTB33 binding partner CTCF.18,19 Further, while the unmethylated palindromic 
sequence TCTCGCGAGA has been attributed to the genomic target of ZBTB33, recent 






Figure 3.5. ZBTB33 ChIP-qPCR at multiple promoter sites within the CCND1 and 
CCNE1 gene promoters. (A) qPCR amplifications before the ChIP-seq DNA library 
preparation. (B) qPCR amplifications after the ChIP-seq DNA library preparation. Letters 















Figure 3.6. Representative ZBTB33 and ZBTB33-HA ChIP-seq profiles at chromosome 
1. ZBTB33 ChIP-seq profiles at chromosome 1 (Chr 1) in three cell lines: K562, 
GM12878, and HeLa. Additionally, ChIP-seq for ZBTB33-HA was performed using an 















Indeed, there are a number of reports that indicate that PARP1 exhibits sequence-specific 
DNA binding capability.20,21 Together, these observations suggest that perhaps the 
ZBTB33 ChIP-seq data sets are reporting on indirect genomic occupations through 
ZBTB33-specific protein interaction partners and not on direct ZBTB33 genomic 
occupation sites. 
To investigate this, we first confirmed through co-immunoprecipitation (co-IP) 
analysis that in HeLa cells, ZBTB33 does form a complex with CTCF (Figure 3.7A). 
This is consistent with previous reports that show a direct interaction between ZBTB33 
and CTCF.22 Further, many reports indicate that CTCF and PARP1 work together to 
mediate DNA methylation status and chromatin organization.23,24 Thus, given that CTCF 
is a binding partner for both ZBTB33 and PARP1, we performed a co-IP to see if 
ZBTB33 and PARP1 associate. Indeed, we show for the first time that ZBTB33 and 
PARP1 do associate within the same protein complex (Figure 3.7B). 
 
Conclusion 
 In our attempts to determine the global genomic occupations of ZBTB33 in 
various cell lines through ChIP-based high-throughput sequencing methods, we have 
identified two major issues. First, the lack of strong formaldehyde generated 
protein:DNA cross-links in ZBTB33:DNA complexes limits the utility of ChIP-exo due 
to the numerous high temperature processing steps that result in premature cross-link 
reversal. Second, it also appears that there may be steps during the ChIP-seq library 
















Figure 3.7. Co-immunoprecipitations of ZBTB33 with PARP1 and CTCF. (A) Co-
immunoprecipitation of ZBTB33 and CTCF in HeLa, LNCaP, and DU145 cells. (B) Co-
immunoprecipitation of ZBTB33 and PARP1 in HEK93 cells using either endogenous 
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Unfortunately, the protein:DNA cross-linking issue for proteins such as ZBTB33 
will be difficult to resolve. It appears that this protein represents a group of transcription 
factor that does not harbor the capability of forming the high-affinity formaldehyde 
mediated protein:DNA cross-links. Numerous cross-linking agents exist for protein:DNA 
interactions, however, only formaldehyde has been shown to be amenable to ChIP 
procedures.25 Thus, there is an urgent need to identify alternative protein:DNA cross-
linking agents that can be utilized in ChIP-based experiments. Furthermore, in order to 
investigate the technical problems caused during library preparation, a step-by-step 
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CELL SPECIFIC KAISO (ZBTB33) REGULATION OF CELL CYCLE 
THROUGH CYCLIN D1 AND CYCLIN E1 
 
Introduction 
 Cytosine methylation in the CpG context (mCpG) is a prevalent and essential 
epigenetic modification required for the maintenance of genomic stability, control of 
gene expression, and the regulation of chromatin structure. Misappropriation of genomic 
DNA methylation patterns has consequently been associated with cancer promotion and 
progression.1,2 Indeed, it has become increasingly evident that nearly all cancers exhibit 
aberrant alterations in DNA methylation preceding tumorigenesis. Further, specific 
patterns of gene hyper-methylation leading to inappropriate transcriptional regulation 
appear to vary between tumor type and grade.3 In gene promoters, DNA methylation 
elicits transcriptional regulation by either preventing or promoting transcription factor 
(TF) binding. Specifically, mCpG sites can be high-affinity targets for specialized TFs, 
termed methyl-CpG binding proteins (MBPs), which mediate chromatin remodeling and 
transcriptional control.4 
 ZBTB33 (also known as Kaiso), is the founding member of the zinc finger (ZF) 
family of MBPs and has been shown to regulate gene expression that is causally linked to 
Reprinted (adapted) with permission from Pozner, A.; Terooatea, T. W.; Buck-Koehntop, 




tumorigenesis.5-11 Importantly, ZBTB33 and its two orthologs, ZBTB4 and ZBTB38, are 
unique amongst other MBPs in that they exhibit bimodal DNA recognition, specifically 
targeting both methylated and sequence-specific nonmethylated DNA sites.12-14 
Intriguingly, ZBTB33 has been shown to recognize methylated DNA and its sequence-
specific site, termed the Kaiso binding site (KBS; TCCTGCNA), utilizing the same set of 
three Cys2His2 ZFs.12,15 Further, this bimodal DNA recognition has afforded ZBTB33 the 
capability of functioning as both a transcriptional repressor and activator depending on 
the sequence context and cellular phenotype.16-23 
 There is mounting evidence that increased ZBTB33 expression and corresponding 
transcriptional activities are associated with cancer progression. In colon cancer cells, 
methyl-dependent repression of CDKN2A by ZBTB33 protects these cells from cell cycle 
arrest.19 Similarly, ZBTB33-null mice crossed with APCMIN/+ mice demonstrated 
resistance to intestinal cancer, implying a direct correlation between the presence of 
ZBTB33 and the disease state.9 ZBTB33 also displays a dynamic subcellular localization 
mediated by its binding partner p120 catenin (p120ctn)24,25 that appears to play a role in its 
disease inducing potential. Specifically, a cytoplasmic-to-nuclear shift has been directly 
linked to the more aggressive phenotypes of breast and prostate cancer (PCa) patient 
tumors.5-7,10 Indeed, a high nuclear ZBTB33 presence correlated with the pathologies, 
histology, and grading in invasive cohorts of high-grade and basal/triple-negative breast 
cancers.5,7,10 Similarly, in PCa an increase in ZBTB33 protein expression and nuclear 
localization correlated with higher tumor grades and Gleason scores, with the highest 
levels of ZBTB33 being found in metastatic PCas.6 However, the subcellular localization 




cytoplasmic ZBTB33 has been linked to poor prognosis in nonsmall cell lung cancer26,27 
and pancreatic cancer.28 Combined, these findings suggest that various cancer types are 
able to modulate the expression levels, cellular localizations, and transcriptional 
responses of ZBTB33 to differentially provide a context specific survival advantage. 
Nonetheless, there is little mechanistic insight into how various cellular phenotypes 
harness the transcriptional capabilities of ZBTB33 to differentially promote and progress 
the disease state. 
 Interestingly, a significant number of findings have implicated ZBTB33 in the 
regulation of cellular proliferation. ZBTB33-knockout mice exhibited increased body 
weight and size, due to splenomegaly resulting from increased splenocyte proliferation,18 
and a dramatic reduction of lateral ventricles indicative of increased embryonic neuronal 
stem cell proliferation.28 Conversely, the small intestinal crypt of transgenic mice over-
expressing ZBTB33 exhibited decreased cell proliferation.29 Further, various ZBTB33 
depletion studies have shown a consequential enhancement of cellular proliferation in 
lung carcinomas (BE1, LTEP-A-2, SPC-A-1),26 HCT 116 cell colon carcinomas,16 SK-
LMS-1 vulva leiomyosarcoma cells,30 HEK293 embryonic kidney fibroblasts,31 and 
K562 blast crisis chronic myeloid leukemia cells when additionally depleted of p120ctn.32 
In contrast, various lines of evidence have also demonstrated a proproliferative function 
for ZBTB33. Indeed, ZBTB33 depletion sensitizes Colo320 and HCT 116 colon cancer 
cell lines to cell cycle arrest after release from serum starvation19 and induces decreased 
cellular proliferation in PC3 PCa cells.11 
Given the evident role for ZBTB33 in regulating cellular proliferation in cancer, 




mediated by the transcriptional activities of ZBTB33 in two different cell lines, HeLa and 
HEK293, both of which have been used extensively for studies of the cell cycle. 
Collectively, our data demonstrate that ZBTB33 transcriptionally regulates the G1-phase 
transition, though ZBTB33 acts as a proproliferative factor in HeLa cells, and an 
antiproliferative in HEK293 cells. Specifically, we have determined that ZBTB33 
directly occupies the promoter regions of cyclin D1 and cyclin E1 in a KBS and methyl-
specific manner, respectively, to enhance cyclin expression in HeLa cells. This ensures 
appropriate Retinoblastoma (RB1) phosphorylation and E2F transcriptional activity, 
facilitating an accelerated G1- to S-phase transition. In contrast, in HEK293 cells 
ZBTB33 indirectly regulates cyclin E abundance resulting in reduced RB1 hyper-





HeLa and HEK293 cells were cultured in DMEM supplemented with 4.5 g/L 
glucose, 2 mM glutamine, and 10% FBS and maintained at 37°C and 5% CO2. Cell 
counting and viability analysis was performed on a Countess Automated Cell Counter 
(Thermo Fisher Scientific). Cell line authentication to confirm lack of cross-







Plasmids and luciferase reporter assay 
The ZBTB33 open reading frame (ORF), obtained from GenScript, was 
transferred into the pcDNA3.1 mammalian expression vector (Thermo Fisher Scientific); 
pCMV-ZBTB33. To put ZBTB33 under control of its endogenous promoter, the original 
CMV promoter was replaced with a DNA fragment PCR amplified from genomic human 
DNA encompassing 2 Kb of DNA upstream of the ZBTB33 transcription start site (TSS); 
pZBTB332K-ZBTB33. To generate the cyclin D1-luciferase reporter plasmids, an 1150 bp 
DNA fragment upstream of the cyclin D1 TSS was PCR amplified from genomic human 
DNA and cloned into the pGL3-Basic Vector (Promega). Mutation of the -1067 KBS was 
completed utilizing standard cloning strategies. The E2F transcription reporter, 6xE2F-
luciferase33 was co-transfected with ZBTB33 siRNAs or overexpressing vectors. The 
Dual-Luciferase Reporter Assays (Promega) were performed 48 h after transfection 
according to manufacturer’s directions and measured on a luminometer. A CMV-Renilla 
construct was used for normalizing the efficiency of the transfection. 
 
RNA interference and RNA/plasmid transfection 
For all ZBTB33 depletion experiments, HeLa or HEK293 cells were transfected 
with either 30 pmol per well (6-well plate) of a scrambled siRNA or one of two siRNAs 
designed against the ZBTB33 transcript (Thermo Fisher Scientific) using Lipofectamine 
RNAiMAX (Thermo Fisher Scientific). Depending on the experiment, RNA or protein 
was extracted from the cells at either 24 or 48 h after transfection as detailed below. For 
mRNA transfection, 30 pmol of GFP mRNA (TRILINK Biotech.) was transfected into a 




and GFP expression was followed by FACS analysis. Plasmid transfections in HeLa cells 
were performed by either using the Neon Transfection System (Thermo Fisher Scientific) 
following the manufacturer’s protocol (2x pulse voltage 1005 V, pulse width 35 ms) or 
Lipofectamine 3000 (Thermo Fisher Scientific). For HEK293 cells, plasmid transfections 
were completed either utilizing a calcium phosphate procedure, as described previously,33 
or Lipofectamine 3000 (Thermo Fisher Scientific). 
 
Immunoblotting 
   Cells were collected in ice-cold PBS and then lysed and sonicated in 1x RIPA 
buffer (10 mM Tris HCl (pH 7.20), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1% 
sodium deoxycholic acid, and 5 mM EDTA) supplemented with an EDTA-free protease 
inhibitor cocktail (Roche). Samples were separated by gel electrophoresis, transferred to 
nitrocellulose or PVDF membranes and immunoblotted.  
 
Antibodies (Abs) 
   For primary antibodies, the following were used: β-actin (Santa Cruz, sc-47778), 
Cyclin D1 (Cell signaling, 2926), Cyclin E (Thermo Fisher, MA5-14336), E2F1 
(ABGENT, AP7593b), E2F2 (Assay Biotechnology, C11025), E2F3 (ABGENT, 
AP14598c), E2F4 (BETHYL Lab, A302-134A), E2F5 (Elabscience, ENT1445), PHH3 
(Millipore, 06-570), RB1 (BD Biosciences, 554136), RB1 pT821 (Abcam, ab32015), 
RB1 pS780 (Abcam, ab173289), ZBTB33 (Santa Cruz, sc-23871). For secondary 
antibodies, the following were used: goat anti-rabbit DyLight 800 (Rockland), goat 




(Thermo Fisher, A-11001), goat anti-rabbit IgG (H+L) Alexa Fluor 546 (Thermo Fisher, 
A-11035). 
 
Semiquantitative RT-PCR (sq-RT-PCR) 
Transfected cells were washed with PBS. Total RNA was isolated by TRIzol 
(Thermo Fisher Scientific) and reverse transcribed using the high capacity cDNA reverse 
transcription kit (Thermo Fisher Scientific) following the manufacturer’s protocols. The 
PCR products were analyzed on a 2% agarose gel. Relevant bands were excised, purified, 
and sequenced for validation. A primer list is available in Table 4.1. 
 
Immunofluorescence, microscopy, and quantitative fluorescence intensity analysis 
 Cells were fed with 10 mM ethynyl deoxyuridine (EdU) under regular growth 
conditions for 30 min and then fixed in 3.7% ice cold formaldehyde in PBS for 15 min 
followed by a 5-min incubation with 100% MeOH at -30°C. Cells were permeabilized 
with PBST (0.5% Triton X-100 in PBS) for 20 min at room temperature (RT) before S-
phase detection using the Click-iT EdU Alexa Fluor 488 Imaging kit (Molecular Probes), 
following the manufacturer’s protocol. Subsequent to adequate washings in 3% BSA in 
PBS, cells were blocked with PBST containing 10% NGS for 1 h at 4°C. Primary Abs 
were incubated overnight at 4°C in PBST with 5% NGS and secondary Abs were 
incubated in the same buffer for 1 h at RT (Table 4.2 for antibody list). Images were 
acquired using a Zeiss Axiovert 200M microscope and captured with SlideBook software 
(Intelligent Imaging Innovations). Quantifications of ZBTB33 mean fluorescence 



















Table 4.1. Primers used for semiquantitive RT-PCR  
Gene Sense Antisense 
β-actin agctacgagctgcctgacgg gatccacacggagtacttgcg 
cyclin D1 gtgcagaaggaggtcctgcc gcttgttcaccaggagcagc 
cyclin E1 gaggaaggcaaacgtgaccg gctcaagaaagtgctgatccc 




















Table 4.2. Primers used for ChIP-qPCR  
Gene Sense Antisense 
CCND1 -1067*  (Figure 4.5, A 
and B; a) 
tttacatctgcttaagtttgcg ttagaatttgccctgggact 
CCND1 +69*     (Figure 4.5, A 
and B; b) 
cacacggactacaggggagtt ctcggctctcgcttctgctg 
CCNE1   (Figure 4.5, D and E; c) cttggtccaggcactatgcc ggctccacaggacctgaccc 
CCNE1   (Figure 4.5, D and E; d) gggtcaggtcctgtggagcc cccgcaagcccttcctggc 
CCNE1   (Figure 4.5, D and E; e) cagaaaggtcttcagagagcc cgccaggcacgccctccc 
CCNE1   (Figure 4.5, D and E; f) cgccgtgtttacattccac gacgcgggagaagtctg 
CCNE1   (Figure 4.5, D and E; g) caaacgtgaccgttgtgagta gatcaggttatgagctccgttc 
ELL3 (Figure 4.5, B and E) tcactcagggagcgcctcattatt atagcctcctgtgttctgccact 
PSMD5 (Figure 4.5E)   










software as described previously.33 
 
Cell proliferation and apoptosis 
 For both fluorometric proliferation and apoptotic assays, cells were harvested 48 h 
post-siRNA transfection. Fluorometric cell proliferation and apoptosis analyses were 
performed following the manufacturer’s protocols for the CyQUANT NF Cell 
Proliferation Assay and CellEvent Caspas-3/7 Green Flow Cytometry Assay kits, 
respectively (Thermo Fisher Scientific). Cell growth curves were performed on siRNA-
transfected cells that were grown in 6-cm plates for 48 h prior to transferring to 24-well 
culture dishes (HeLa; 5x104 cells/well, HEK293; 1.5x104 cells/well), and then cultured 
for an additional 0-4 days. Cell numbers were counted daily using a Countess Automated 
Cell Counter (Thermo Fisher Scientific). 
 
Cell cycle analysis by FACS 
Cells were harvested 48 h post-siRNA transfection and fixed/permeabilized in 
ice-cold 1:1 PBS:MeOH-acetone [4:1 (v:v)] while vortexing. Subsequent to adequate 
washings in FACS buffer (0.5% BSA, 0.05% NaN3 in PBS), cells were incubated over 
night with 0.1% Triton X-100, 50 mg/ml RNase A, and 50 mg/ml propidium iodide 
(Sigma) in FACS buffer at 4 °C. Cells were analyzed with a FACScan flow cytometer 








All above mentioned experiments were repeated three to four times independently 
of each other. Data were analyzed with Excel software using Student’s t-test (Microsoft). 
P-values (two-tailed) of 0.05 were considered statistically significant. For multiple group 
analyses, χ2-values were applied. 
 
ChIP-qPCR 
HeLa cells were fixed with 1% formaldehyde for 10 min to cross-link 
protein:DNA complexes, followed by a quench with 125 mM glycine. The cell lysis, 
chromatin isolation, and immunoprecipitation (IP) reaction procedures were performed 
using materials from the commercially available Zymo-Spin ChIP Kit (Zymo Research) 
following the manufacturer’s instructions. In short, after lysis, washing and chromatin 
isolation, a Diagenode Bioruptor Standard sonication device (run at max amplitude for 5 
x 15 min in ice water) was used to shear the cross-linked DNA down to 100 - 400 bp 
fragments. The IP was carried out using an Abs against ZBTB33 (6F8, Santa Cruz). After 
quantitating the amount of genomic DNA by PicoGreen assay, equal amounts of ChIP 
amplicons for each sample were prepared with the SYBR Green Real-Time PCR Master 
Mix (Thermo Fisher Scientific) and analyzed by qPCR on a QuantStudio 6 Flex Real-
Time PCR System (Thermo Fisher Scientific). The fold enrichment was determined 
based on the cycle differences after normalization to input DNA. A region from the ELL3 
gene was also amplified as a negative control. The qRT-PCR primers are listed in Table 






To achieve ZBTB33 depletion, 3x106 HeLa cells per replicate were transfected 
with either ZBTB33 specific or control siRNAs as discussed above. Twenty four hours 
after transfection, cells were washed with 0.01 M PBS (pH 7.4) and resuspended in 
TRIzol (Thermo Fisher Scientific) prior to RNA extraction with the Direct-zol RNA Kit 
(Zymo Research). Prior to sequencing analysis, RNA aliquots were reverse transcribed 
and the amount of ZBTB33 determined by qPCR as described above, utilizing HPRT1 as 
a normalization control, to ensure that sufficient ZBTB33 knock-down was achieved. For 
RNA-seq, RNA quality control measurements, purification, library construction and 
sequencing were all performed by the High-Throughput Genomics Core within the 
University of Utah Huntsman Cancer Institute (HCI). In short, RNA quality was 
measured on a Bioanalyzer RNA 6000 Nano Chip. Small and long directional RNA-seq 
libraries were constructed using the Illumina TruSeq Standard mRNA Sample 
Preparation Kit v2 with poly(A) selection. Libraries were sequenced with a 50 bp single-
end run on the Illumina HiSeq 2000 platform. 
 
Whole genome shotgun bisulfite sequencing (WGSBS) 
Genomic DNA was isolated from 20x106 HeLa cells using the DNeasy Blood and 
Tissue Kit (QIAGEN). DNA quality control measurements, bisulfite (BS) conversion, 
purification, library construction, and sequencing were all performed by the High-
Throughput Genomics Core within the University of Utah HCI. The BS conversion and 
library construction was performed using the EpiGnome/TruSeq DNA Methylation Kit 




containing unmethylated lambda DNA (Promega) as a control. Following purification, 
adapter-ligated DNA was generated using EpiGnome polymerase. Adapter-ligated DNA 
molecules were enriched by 10 cycles of PCR, concentration normalized and sequenced 
with a 125-cycle paired-end run on the Illumina HiSeq 2000 platform. 
 
Sequencing data analyses 
RNA-seq and WGSBS fastq files were aligned to the human genome (hg19) using 
Novoalign (Novocraft, Inc.) and peak called with the USeq suite.34 RNA-seq reads were 
aligned with all known and theoretical splice junctions using the following parameters: -r 
All 50 -t 40 -o SAM 90 –k. The USeq NovoalignParser application was then used to 
parse the alignment files into binary point data by setting the posterior probability to 0 
and alignment score threshold to 60. The MultipleReplicaDefinedRegionScanseqs USeq 
application, which utilizes the DESeq R package,35 identified statistically significant 
differentially expressed genes between cells treated with the scrambled and ZBTB33 
siRNAs. The WGSBS fastq data were aligned in Novoalign bisulfite mode using the 
following parameters: -oSAM -rRandom -t240 -h120 -b2. The sam alignments were 
sorted with the Picard SortSam.jar script and all duplicates removed using the Picard 
MarkDuplicates.jar script for WGSBS datasets. The results were converted into .bam 
files and indexed using Samtools.36 Peak calling was performed with the USeq 
NovoalignBisulfiteParser to parse the alignments into four binary PointData sets 
containing the number of observed converted Cyt and nonconverted Cyt at each reference 






IPA (www.ingenuity.com) and GSEA37 analyses tools were used to compute 
significant biological pathways enriched in the depleted ZBTB33 RNA-seq dataset 
relative to the control. For IPA analysis, only genes with ≥2-fold expression differences 
and P-values lower than 0.01 calculated by USeq (see above) were used. The obtained 
canonical pathways with false discovery rate (FDR) values lower than 0.01 were 
considered significant. GSEA was run to identify significant up- and down-regulated 
expression patterns using the c2.all.v3.0.symbols.gmt gene set collection from the Broad 
Institute Molecular Signatures Database. Only gene sets with a minimum size of 10 in the 
MsigDB v3.0 c2 curated database were selected. The Kolmogorov–Smirnov statistics 
with a cumulative null distribution of 1000 permutations was used to calculate the 
enrichment scores of each gene set. Furthermore, all gene sets with a Benjamini–
Hochberg and GSEA FDR values lower than 0.01 were deemed significant. 
 
Results 
ZBTB33 is required for proper HeLa cell proliferation but has 
 an inhibitory effect on HEK293 cell growth 
ZBTB33 depletion studies were performed by using two different ZBTB33 
targeting siRNA sequences or a scrambled (Scr) siRNA control in both HeLa and 
HEK293 cells. The efficiency of RNA transfection was measured and determined to be 
~70% and ~96% in HeLa and HEK293 cells, respectively (Figure 4.1A and 4.1B). 
Despite the fact that HeLa cells have been transformed by the human papilloma virus 
















Figure 4.1. ZBTB33 depletion induces differential proliferation trends in HeLa and 
HEK293 cells. (A and B) FACS analysis of GFP expression in HeLa and HEK293 cells 
48 h after GFP mRNA transfection. (C and D) Immunoblot analyses of ZBTB33 protein 
expression in HeLa and HEK293 cells after transfection with either a scrambled (Scr) or 
ZBTB33 targeting siRNAs.(E and F) Fluorometric quantitation of cell viability after 
ZBTB33 depletion. (G and H) FACS analysis of apoptosis in ZBTB33 depleted HeLa 
and HEK293 cells after 48 h. (I and J) growth curves of HeLa and HEK293 cells after 


































which their response to ZBTB33 depletion can be evaluated. Immunoblot analyses 
confirmed that appreciable ZBTB33 depletion was achieved at the protein level 48 h after 
siRNA transfection (Figure 4.1C and 4.1D). Subsequent fluorescence quantification of 
cell viability in ZBTB33 depleted HeLa cells showed a marked reduction (Figure 4.1E). 
In contrast, but consistent with previous observations,31 ZBTB33 depleted HEK293 cells 
exhibited a significant increase in cell viability (Figure 4.1F). Notably, for both cell lines 
the observed alterations in cell viability appeared to occur without deviations in the 
extent of cell death (Figure 4.1 G and H), indicating that ZBTB33 depletion in HeLa cells 
leads to decelerated cell proliferation while stimulating HEK293 proliferation. As further 
confirmation, direct cell counting similarly showed that ZBTB33 depletion induced 
substantial deceleration of HeLa proliferation (Figure 4.1I), and a significant acceleration 
of HEK293 proliferation (Figure 4.1J). 
 
ZBTB33 regulates the G1- to S-phase transition 
 Next, we sought to identify which cell cycle checkpoint(s) is/are regulated by 
ZBTB33 through monitoring changes in ZBTB33 protein levels during each cell cycle 
phase. Double immunostaining for ZBTB33 and the M-phase marker PHH3 was 
conducted on HeLa and HEK293 cells in combination with a 30 min exposure to EdU for 
S-phase labeling (Figure 4.2A and C). Quantification of the mean fluorescence intensities 
in HeLa cells showed significant differences in ZBTB33 abundance between the various 
cell cycle phases (Figure 4.2B), whereas in HEK293 cells the amount of ZBTB33 was 
nearly identical across all cell cycle phases (Figure 4.2D). These findings indicate that in 












Figure 4.2. ZBTB33 abundance correlates with the regulation of cell cycle progression in 
HeLa cells. (A and C) HeLa and HEK293 cells, respectively, 30 min after EdU pulse 
under regular growth conditions to visualize cells in S-phase, were additionally stained 
for phospho-histone 3 (PHH3-blue, M-phase) and ZBTB33 (green). From these images, 
the mean fluorescence intensity (normalized with cell area) of ZBTB33 staining per cell 
in S-, G1-, and M-phase was plotted (B and D). Because the extent of G1 is by far longer 
than G2 duration, we approximated that PHH3 and EdU negative cells were 
overwhelmingly in G1. Two random fields were analyzed per cell line. Numbers in the 
plots reflect the number of cells measured within each cell cycle phase. Scale bars, 20 
µm. (E and G) FACS analysis of cell cycle phase distributions after ZBTB33 depletion in 
HeLa, and HEK293 cells, respectively. From triplicates of the FACS data, the percent 
populations of cells in each cell cycle phase were plotted (F and H). Error bars reflect the 




















course and that ZBTB33 mainly plays a role in G1- and M-phase progression.  
To interrogate this further, cell distribution across the different cell cycle phases  
were determined by FACS analysis after ZBTB33 depletion using propidium iodide 
staining. Significantly, HeLa cells exhibited a substantially increased G1-phase 
population at 48 h post-ZBTB33 depletion concomitant with a decreased S-phase relative 
to the control (Figure 4.2E and F), indicating that ZBTB33 depletion was sufficient to 
induce a G1 arrest in HeLa cells. ZBTB33 depleted HEK293 cells on the other hand, 
showed a moderately significant decrease in G1-phase cell population relative to the 
control (Figure 4.2G and H). Thus, these observations suggested that ZBTB33 is 
necessary for proper G1-phase progression in HeLa cells while it has an inhibitory effect 
on the G1-phase in HEK293 cells. 
 
Gene expression profiling in ZBTB33 depleted HeLa cells 
To begin delineating the mechanism by which ZBTB33 modulates HeLa cell 
growth, RNA-seq was utilized to compare global transcriptome alterations between 
normal and ZBTB33 depleted cells. In the absence of ZBTB33, a substantial number of 
genes (758) demonstrated a significant transcriptional alteration relative to the control. 
Interestingly, it can be seen that while ZBTB33 transcriptional activities are largely 
repressive in HeLa cells (512 genes), there are an appreciable number of genes in which 
ZBTB33 also appears to mediate transcriptional activation (246 genes) (Figure 4.3A). 
Thus, in the global context these RNA-seq results reaffirm that ZBTB33 indeed has the 
capability of being a bimodal regulator of transcriptional activity in HeLa cells. To 


















Figure 4.3. Identification of ZBTB33-regulated transcriptional signature in HeLa cells. 
(A) Unsupervised hierarchical clustering heatmap from RNA-seq data depicting gene 
transcripts exhibiting a two-fold up- (green) or downregulation (red) after ZBTB33 
depletion relative to the control. (B) Altered genes depicted in (A) were subjected to 
Ingenuity Pathway Analysis (IPA) to identify biological pathways uniquely modulated by 
ZBTB33. Only the 12 most statistically significant (all P < 0.05) downregulated 
pathways that were also identified in our GSEA analysis are depicted. (C-E) GSEA 
correlation plots37 depicting ZBTB33 regulation of cell cycle genes (C), genes associated 
with G1- to S-phase transition (D), and (E) genes associated with DNA replication. The 
barcode plot indicates the position of the genes in each gene set; red and blue represent 
positive and negative Pearson correlations with ZBTB33 depletion, respectively. (F) 
Hierarchical clustering heatmap illustrating differential expression of genes affecting cell 
cycle in ZBTB33 depleted HeLa cells. The heatmap color represents Z-score normalized 
isotig number of for each gene. Blue indicates high gene expression while red indicates 
































altered genes in our RNA-seq data, we performed both IPA and GSEA analyses (Figure 
4.3B-4.3E and Table 4.3). Both of these analyses indicated that as the 
immunofluorescence and FACS data predicted, ZBTB33 clearly modulates genes 
associated with regulation of the G1- to S-phase transition in HeLa cells. 
 
ZBTB33 regulates cyclin D1 and cyclin E1 expression 
Having established a definitive causal link between ZBTB33 transcriptional 
activities and the G1- to S-phase transition in HeLa cells, we sought to identify the cell 
cycle regulators that are most likely direct ZBTB33 gene targets. Thus, a list of candidate 
cell cycle regulator genes was mined from the RNA-seq data using the above discussed 
GSEA results. From this analysis, 30 candidate genes were found to have a statistically 
significant differential expression between the control and ZBTB33 depleted cells (Figure 
4.3F). Of particular note, two master regulators of G1- to S-phase transition, cyclin D1 
and cyclin E1,40 were amongst the most significantly downregulated genes upon ZBTB33 
depletion in HeLa cells. Direct repression of cyclin D1 by ZBTB33 has been reported 
previously in a number of cancerous cell lines,16,17 however, our findings here suggest 
that ZBTB33 is transcriptionally activating cyclin D1 in HeLa cells. Similarly, in A549 
and SPC cells, ZBTB33 transcriptional activities have been associated with repression of 
cyclin E, though it has not been definitively discerned as to whether this is a direct or 
indirect consequence.17 
 To compare our HeLa cell findings with HEK293 cells and to investigate whether 
the observed changes in mRNA transcript levels translate at the protein level, we 




Table 4.3. Gene lists from the GSEA correlation plots depicted in Figure 4.3C-E 
 































CDAN1 CCND1 GMNN 
CDC14A CCNG2 MCM10 
CHEK1 CDK7 POLD4 
CHEK2 CDKN1B RFC2 
DTX4 CREB3L1 RFC3 
HDAC2 CREB3L3 RFC4 
HDAC3 MNAT1 RPS27A 
HDAC4 MYC UBB 
HDAC5 TFDP2 UBC 
HDAC6   
MAD1L1   
MAD2L1   
MAD2L2   
PTPRA   
SMAD4   
TBC1D8   




of control and ZBTB33 depleted cells. In HeLa cells, the quantities of cyclin D1 and 
cyclin E1 at both the mRNA and protein levels were significantly lower in ZBTB33 
depleted cells (Figure 4.4A-4.4D). In contrast, transcript levels of cyclin D1 and cyclin 
E1 were seemingly unaffected by ZBTB33 depletion in HEK293 cells (Figure 4.4A). 
Interestingly, at the protein level cyclin D1 also exhibited no change after ZBTB33 
depletion (Figure 4.4B and 4.4F), however, cyclin E displayed a significant two-fold 
increase in HEK293 cells (Figure 4.4B and 4.4E). cyclin E cellular abundance is 
regulated predominantly at the levels of gene transcription and ubiquitin-dependent 
proteolysis.41 Accordingly, the discrepancy between increased cyclin E protein levels and 
unaffected mRNA expression suggests that posttranscriptional ubiquitin-dependent 
regulation of this protein is activated in ZBTB33 depleted HEK293 cells. Together, these 
findings indicate that in HeLa cells ZBTB33 plays a direct role in transcriptionally 
mediating cellular levels of cyclin D1 and cyclin E1, whereas in HEK293 cells 
transcription of these genes appears to be ZBTB33 independent. 
 
ZBTB33 directly occupies both cyclin D1 and cyclin E1 promoter regions 
 in HeLa Cells 
It was shown previously that repression of the cyclin D1 gene in MCF-7 and HCT 
116 cells required dual occupation by ZBTB33 at both a -1067 location that contains the 
KBS as well as a  mCpG containing site at the +69 position.16 It was further confirmed 
that occupation at the +69 position is methyl-dependent. To resolve the perceived 
discrepancy by which ZBTB33 mediates transcriptional activation of cyclin D1 in HeLa 



















Figure 4.4. ZBTB33 regulates cyclin E1 and cyclin D1 expression. (A) Relative mRNA 
expression levels of ZBTB33, cyclin E1, and cyclin D1 in HeLa and HEK293 cells 
determined after ZBTB33 depletion by semiquantitative RT-PCR. (B) Immunoblot 
analysis for ZBTB33, cyclin E and cyclin D1 in HeLa and HEK293 cells after ZBTB33 
depletion. The low molecular weight cyclin E bands are due to protease or alternative 
splicing processing.33,43 (C-F) Band intensities from three independent immunoblots 
were quantitated and normalized to β-actin to determine the protein expression levels of 
cyclin E and cyclin D1 after ZBTB33 depletion relative to the Scr control in both HeLa 









1067 and +69 loci and analyzed these findings in the context of global methylome 
mapping in HeLa cells. From ChIP-qPCR we observed a significant occupation of 
ZBTB33 at the -1067 KBS containing site, but no occupation at the CpG-containing +69 
site (Figure 4.5A and B). Interestingly, global methylome analysis demonstrated that in 
HeLa cells the cyclin D1 promoter harbors a low methylation incidence (Figure 4.5A). 
This finding is consistent with the lack of ZBTB33 occupation at the +69 CpG site and 
reaffirms that ZBTB33 indeed binds this region in a methyl-dependent manner. 
To corroborate these findings, we assessed the ability of ZBTB33 to regulate 
luciferase expression under control of either a minimal wild-type (WT) or mutated cyclin 
D1 promoter that considerably altered the -1069 KBS core (Figure 4.5C). As anticipated, 
luciferase activity of the mutated cyclin D1 promoter was significantly reduced relative to 
the WT (Figure 4.5C). Moreover, co-transfection of either the WT or mutant cyclin D1 
promoter-reporter plasmid with ZBTB33 siRNAs resulted in a similar decrease in 
luciferase activity (Figure 4.5C). Combined, these data substantiate that the ability of 
ZBTB33 to transcriptionally activate cyclin D1 in HeLa cells is solely dependent on the 
integrity of the -1067 KBS loci.  
Finally, we sought to determine if ZBTB33 also directly occupies the cyclin E1 
promoter. Unlike the cyclin D1 promoter, cyclin E1 does not have a KBS site within 
approximately -1000 base pairs of the TSS, but according to our methylome analysis does 
have regions of high CpG methylation (Figure 4.5D). ChIP-qPCR analysis for ZBTB33 
binding in several of these regions demonstrated that it indeed appears to preferentially 
occupy mCpG sites in the promoter but not within intergenic regions (Figure 4.5E). 












Figure 4.5. ZBTB33 directly occupies and regulates cyclin D1 and cyclin E1 gene 
promoters. (A and D) WGSBS read coverage tracks depicting percent DNA methylation 
(mCpG) levels at cyclin D1 and cyclin E1 promoters. Regions within each promoter 
amplified by ChIP-qPCR are indicated (gray bars). (B)  ChIP-qPCR analysis at the cyclin 
D1 promoter in HeLa and HEK293 cells at known ZBTB33 occupation sites, including a 
KBS-containing location at -1067 and a CpG containing site at the +69 position. (C) 
Scheme depicting design of the wild type (WT) and KBS-mutated minimal cyclin D1 
promoter-luciferase reporter plasmids (top). The minimal WT or KBS-mutated cyclin D1 
promoter-luciferase reporter plasmids were co-transfected with ZBTBT33 siRNAs, and 
luciferase activity was quantitated (bottom). Luciferase reads were normalized to Renilla 
activity. (E) ChIP-qPCR analysis for ZBTB33 occupation of the cyclin E1 promoter in 
HeLa and HEK293 cells at various CpG-containing regions. The PSMD5 gene promoter 
was selected as a positive control in HEK293 cells based on publicly available ZBTB33 
ChIP-seq data (GSM1334009 and GSM803504). Error bars reflect mean_S.D.; *, p < 














































DNA methyltransferase inhibitor 5-aza-2-deoxycytidine abrogates ZBTB33 binding 
(Figure 4.5E). Although promoter methylation is typically associated with gene silencing, 
recent large-scale DNA methylation profiling studies have shown that depending on the 
cellular context, hyper-methylated promoters are also found near highly transcribed 
genes.44-46 Thus, our findings suggest that ZBTB33 has the ability to function as a 
methyl-dependent activator of gene activity. To the best of our knowledge, this is the 
first evidence that ZBTB33 directly occupies and transcriptionally modulates cyclin E1 
expression to affect cell cycle progression. Together, our findings demonstrate that in 
HeLa cells ZBTB33 is a direct transcriptional regulator of two key cell cycle genes that 
function in the G1- to S-phase transition. Finally, ChIP-qPCR analysis of cyclin D1 and 
cyclin E1 promoter occupancy by ZBTB33 in HEK293 cells reveals a lack of ZBTB33 
association with these promoters (Figure 4.5B and 4.5E), further confirming that 
ZBTB33 does not regulate cyclin D1 transcription and indirectly regulates cyclin E 
abundance in HEK293 cells. 
 
Aberrant RB1-E2F activity in ZBTB33 depleted cells 
To establish a causal relationship between ZBTB33 regulation of cyclin D1 and 
cyclin E1 transcription, HeLa cell proliferation and G1- to S-phase transition, we 
assessed phosphorylation of RB1 and subsequent E2F activity in ZBTB33 depleted cells. 
The cyclin D1-cyclin E-RB1-E2F pathway functions as a bi-stable switch regulating G1-
phase transition upon cellular commitment to proliferate.47 At the beginning of G1, E2F 
is bound and repressed by RB1. With sufficient stimulation, activities of cyclin D/Cdk4,6 




its repression of E2F.40,48,49 Of note, it has been previously determined that the HPV E7 
oncoprotein binding site on RB1 is separable.  
 As a first analysis, we utilized a pan-RB1 antibody to discern whether global 
levels of RB1 protein were affected in either HeLa or HEK293 cells after ZBTB33 
depletion. HEK293 cells harbor a mixture of both hyper- and hypo-phosphorylated RB1 
isoforms (Figure 4.6A).51 By comparison, HeLa cells typically show a predominant 
single RB1 band,52,53 consistent with the hyper-phosphorylated form as observed in these 
studies (Figure 4.6A). Notably, Figure 4.6A clearly shows that in either cell line, there 
are no detectably significant changes in total pan-RB1 protein levels indicating that 
ZBTB33 depletion did not sequester RB1 for further HPV E7 proteolysis, or reduce RB1 
degradation in HEK293 cells.  
Next, an antibody specific to RB1 phosphorylated at S780 (pRB1S780) was 
selected as this site is exclusively phosphorylated by the cyclin D/Cdk(4/6) complexes. 
Similarly, an antibody specific to phosphorylated T821 (pRB1T821) was used to evaluate 
cyclin E/Cdk2 activity. Consistent with the observed decrease in cyclin D1 levels (Figure 
4.4B and 4.4D), ZBTB33 depleted HeLa cells exhibited reduced pRB1S780 (Figure 4.6A). 
Although ZBTB33-depleted HeLa cells harbored reduced cyclin E levels (Figure 4.6B) 
and 4.6C), they did not show a corresponding significant decrease in pRB1T821 (Figure 
4.6A). These unexpected results may be attributed to compensatory activity of the cyclin 
A/Cdk2 complex, which can also act to phosphorylate T821.54 
Proper activation of the E2F family of transcription factors is essential for 
adequate G1- to S-phase transition. At early G1-phase, E2F proteins are bound to and 











Figure 4.6. ZBTB33 regulates the RB1-E2F pathway. (A) Representative immunoblots 
for whole (pan) and phosphorylated RB1 in HeLa and HEK293 cells (100 µg and 12 µg 
total protein per lane, respectively) after ZBTB33 depletion. Note, HeLa and HEK293 
β-actin immunoblots were analyzed using different exposure intensities. (B, C) A 
6xE2F-luciferase reporter ≠was transfected into control and ZBTB33-depleted HeLa and 
HEK293 cells and luciferase activity quantitated. Luciferase reads, normalized to Renilla 
activity, represent endogenous E2F activity. (D) Immunoblot analysis for ZBTB33 in 
HeLa cells transfected with ZBTB33 overexpression plasmids under control of either a 
2-Kb minimal endogenous ZBTB33 promoter or a highly active CMV promoter. (E, F) 
A 6xE2F-luciferase reporter was transfected into mock-control or ZBTB33 
overexpressing cells demonstrating dose-dependent E2F activity in HeLa cells, and a 
decreased E2F activity in HEK293 cells. (G) Representative immunoblots for E2F1-5 
proteins in HeLa and HEK293 cells after ZBTB33 depletion*p < 0.05, **p < 0.01, ***p 















Figure 4.7. Diagram illustrating the canonical and proposed ZBTB33 mediated cyclin 
D1/cyclin E1/RB1/E2F pathways. The canonical cyclin D1/cyclin E1/RB1/E2F pathway 
regulates G1- to S-phase progression (top) in comparison to proposed models for the 








activity of cyclin D/Cdk(4,6) and cyclin E/Cdk2 complexes are induced to initiate RB1 
hyper-phosphorylation, relieving E2F repression.55 Given that ZBTB33 depletion was 
from the regions of RB1 required to impose cell cycle arrest. As evidence, mutant RB1 
proteins deficient in E7 binding retain their ability to induce cell cycle arrest and repress 
transcription of E2F target genes.50 
As a first analysis, we utilized a pan-RB1 antibody to discern whether global 
levels of RB1 protein were affected in either HeLa or HEK293 cells after ZBTB33 
depletion. HEK293 cells harbor a mixture of both hyper- and hypo-phosphorylated RB1 
isoforms (Figure 4.6A).51 By comparison, HeLa cells typically show a predominant 
single RB1 band,52,53 consistent with the hyper-phosphorylated form as observed in these 
studies (Figure 4.6A). Notably, Figure 4.6A clearly shows that in either cell line, there 
are no detectably significant changes in total pan-RB1 protein levels indicating that 
ZBTB33 depletion did not sequester RB1 for further HPV E7 proteolysis, or reduce RB1 
degradation in HEK293 cells.  
Next, an antibody specific to RB1 phosphorylated at S780 (pRB1S780) was 
selected as this site is exclusively phosphorylated by the cyclin D/Cdk(4/6) complexes. 
Similarly, an antibody specific to phosphorylated T821 (pRB1T821) was used to evaluate 
cyclin E/Cdk2 activity. Consistent with the observed decrease in cyclin D1 levels (Figure 
4.4B and 4.4D), ZBTB33 depleted HeLa cells exhibited reduced pRB1S780 (Figure 4.6A). 
Although ZBTB33-depleted HeLa cells harbored reduced cyclin E levels (Figure 4.6B) 
and 4.6C), they did not show a corresponding significant decrease in pRB1T821 (Figure 
4.6A). These unexpected results may be attributed to compensatory activity of the cyclin 




Proper activation of the E2F family of transcription factors is essential for 
adequate G1- to S-phase transition. At early G1-phase, E2F proteins are bound to and 
repressed by hypo-phosphorylated RB1 (Figure 4.7). With sufficient stimulation, the 
activity of cyclin D/Cdk(4,6) and cyclin E/Cdk2 complexes are induced to initiate RB1 
hyper-phosphorylation, relieving E2F repression.55 Given that ZBTB33 depletion was 
demonstrated to alter RB1 phosphorylation, we sought to determine the effect of 
ZBTB33 depletion and overexpression on E2F activity utilizing a 6xE2F luciferase 
reporter assay.33 As expected, ZBTB33 depleted HeLa cells displayed significantly 
reduced endogenous E2F activity (Figure 4.6B), and concomitantly a concentration-
dependent increase in E2F activity with ZBTB33 overexpression (Figure 4.6D and 4.6E). 
Notably, the observed increase in Cyclin E abundance in ZBTB33 depleted HEK293 
cells (Figure 4.4B and 4.4E) resulted in an increase of pRB1T821 (Figure 4.6A). 
Accordingly, ZBTB33 depletion in HEK293 cells resulted in increased E2F activity 
(Figure 4.6C), while ZBTB33 overexpression inhibited E2F function (Figure 4.3F). 
Interestingly, many of the genes identified by the RNA-seq analysis to be dysregulated by 
ZBTB33 depletion in HeLa (Figure 4.3F) are also established E2F targets.42 Furthermore, 
RNA-seq analysis also showed differential expression of several E2F transcription factors 
upon ZBTB33 depletion in HeLa cells (Figure 4.3F). In general, immunoblot analyses 
confirmed these observations at the protein level, particularly showing increased E2F1 
and decreased E2F2 and E2F3 proteins after reduction of ZBTB33 (Figure 4.6G). 
Nonetheless, a direct ZBTB33 regulation of E2F gene transcription is difficult to discern 
given that the E2F proteins also regulate their own expression.51 While this provides 




E2F activity is differentially modulated by ZBTB33 between HeLa and HEK293 cells. 
 
Discussion 
Dysregulated expression of G1-phase cyclins has been correlated with the genesis 
of a large proportion of human malignancies.56 In particular, tumor upregulation of cyclin 
D1 and cyclin E is generally correlated with poor prognosis. Indeed, the activation of 
cdk4 and cdk6 by cyclin D1 along with the association of cyclin E with cdk2, function as 
gatekeepers at the G1 restriction checkpoint (R-point) to regulate G1- to S-phase 
transition and initiation of DNA replication. Consequently, overexpression of these genes 
has been implicated in the acceleration of cell cycle transition through the R-point that 
promotes genetic instability and uncontrolled cell proliferation by eliminating p53/p21 
regulatory constraints.56 
Interestingly, the observed increase in ZBTB33 expression and nuclear 
localization associated with high-grade and poor prognosis in human breast and prostate 
tumors appears to correlate with tumor phenotypes harboring increased cyclin D1 and 
cyclin E levels. ZBTB33 has been reported to play a critical role in TGFβ signaling 
regulation of metastasis in breast cancer, such that increasing levels of ZBTB33 are 
associated with decreased breast cancer metastasis-free survival times.5,7,10 Likewise, 
cyclin D1 is one of the most commonly amplified genes and frequently overexpressed 
proteins in breast cancer,57 and the level of cyclin E expression is used as a powerful 
clinical predictor of survival status in breast cancer patients.58 Elevated levels of either 
ZBTB33 or cyclin D1 in primary prostate tumors have also been shown to coincide with 




been identified as critical co-activators of androgen-dependent transcription and cell 
cycle progression in PCa cells, suggesting that their aberrant expression in tumors may 
contribute to persistent activation of androgen receptor function, even during androgen 
ablation therapy.60,62  
While it has been determined that ZBTB33 can transcriptionally modulate cyclin 
D1 and cyclin E in several cell lines,16,17 it has thus far been shown to directly or 
indirectly transcriptionally repress these cyclins and subsequently reduce their 
proliferation capabilities. However, these findings are contradictory to the established 
proproliferative characteristic of G1 cyclins observed in high-grade tumors. Interestingly, 
similar to our observations in HeLa cells, ZBTB33 depletion induced a decreased cellular 
proliferation in PC3 cells, a cell line model for high grade PCa.11 Given the increasing 
evidence that various cancer phenotypes are able to differentially modulate the 
expression levels, cellular localizations and transcriptional responses of ZBTB33, and the 
correlation between ZBTB33 activities in the more aggressive forms of breast and 
prostate tumors, it stands to reason that in addition to its established role in 
transcriptionally inducing epithelial-to-mesenchymal transition (EMT) programming in 
high grade breast and prostate tumors,59,63-65 ZBTB33 may also mediate cellular 
proliferation through upregulation of G1 cyclins. As evidence for a possible mechanism 
by which ZBTB33 may mediate proproliferative activities in cancer, we show here for 
the first time a positive causal correlation between cell proliferation and ZBTB33, cyclin 
D1 and cyclin E expression levels that appears to be cell-type specific (Figure 4.7).  
Repression of cyclin D1 was previously shown to require ZBTB33 cooccupation 




observed that activation of cyclin D1 was facilitated solely through occupation at the -
1067 KBS region and that occupation of the +69 was abrogated by the lack of DNA 
methylation at this site. Thus, these findings suggest that altering the methylation status at 
the +69 site may provide a novel mechanism by which different cell types can direct the 
transcriptional activities of ZBTB33 to be repressive or activating at the cyclin D1 
promoter. In contrast, activation of the cyclin E1 promoter appears to be solely reliant on 
methyl-dependent CpG recognition. Further, we demonstrated in HeLa cells that 
ZBTB33 is absolutely necessary for proper cyclin D1 and cyclin E expression and that it 
subsequently plays a proproliferative role by positively regulating the RB1-E2F pathway 
(Figure 4.7). Conversely, ZBTB33 depletion in HEK293 cells resulted in an accelerated 
cell proliferation due to an indirect increase in cyclin E abundance (Figure 4.7), 
suggesting that in HEK293 ZBTB33 normally functions to restrain cyclin E protein 
levels. Thus, together we have provided novel mechanistic insight into how various cell 
phenotypes may be able to differentially tune the transcriptional activities of ZBTB33 at 
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